

# Liang Cheng

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/502162/publications.pdf](https://exaly.com/author-pdf/502162/publications.pdf)

Version: 2024-02-01

1,123  
papers

44,959  
citations

1685

101  
h-index

7022

148  
g-index

1218  
all docs

1218  
docs citations

1218  
times ranked

32739  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bladder cancer: Epidemiology, staging and grading, and diagnosis. <i>Urology</i> , 2005, 66, 4-34.	1.4	853
2	Cholesteryl Ester Accumulation Induced by PTEN Loss and PI3K/AKT Activation Underlies Human Prostate Cancer Aggressiveness. <i>Cell Metabolism</i> , 2014, 19, 393-406.	16.0	703
3	The Role of Polarization in Photocatalysis. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 10061-10073.	14.7	648
4	Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. <i>Modern Pathology</i> , 2018, 31, 24-38.	5.8	337
5	Risk of prostate carcinoma death in patients with lymph node metastasis. <i>Cancer</i> , 2001, 91, 66-73.	4.1	325
6	LncRNA2Target v2.0: a comprehensive database for target genes of lncRNAs in human and mouse. <i>Nucleic Acids Research</i> , 2019, 47, D140-D144.	14.2	318
7	Whole Slide Imaging Versus Microscopy for Primary Diagnosis in Surgical Pathology. <i>American Journal of Surgical Pathology</i> , 2018, 42, 39-52.	4.0	309
8	Current Progress in CAR-T Cell Therapy for Solid Tumors. <i>International Journal of Biological Sciences</i> , 2019, 15, 2548-2560.	6.4	305
9	OCT4 Staining in Testicular Tumors. <i>American Journal of Surgical Pathology</i> , 2004, 28, 935-940.	4.0	283
10	Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. <i>Cancer</i> , 2004, 100, 2362-2366.	4.1	275
11	Small cell carcinoma of the urinary bladder. <i>Cancer</i> , 2004, 101, 957-962.	4.1	273
12	Clear Cell Papillary Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1239-1245.	4.0	256
13	Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. <i>Human Pathology</i> , 2010, 41, 781-793.	2.4	249
14	DincRNA: a comprehensive web-based bioinformatics toolkit for exploring disease associations and ncRNA function. <i>Bioinformatics</i> , 2018, 34, 1953-1956.	4.2	248
15	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. <i>Modern Pathology</i> , 2011, 24, 48-57.	5.8	243
16	Grading of renal cell carcinoma. <i>Histopathology</i> , 2019, 74, 4-17.	3.1	239
17	Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma. <i>Molecular Cancer</i> , 2017, 16, 16.	20.3	232
18	An Immune-Related Six-lncRNA Signature to Improve Prognosis Prediction of Glioblastoma Multiforme. <i>Molecular Neurobiology</i> , 2018, 55, 3684-3697.	4.2	222

#	ARTICLE	IF	CITATIONS
19	Molecular pathology of lung cancer: key to personalized medicine. <i>Modern Pathology</i> , 2012, 25, 347-369.	5.8	219
20	Characterization of long non-coding RNA-associated ceRNA network to reveal potential prognostic lncRNA biomarkers in human ovarian cancer. <i>Oncotarget</i> , 2016, 7, 12598-12611.	1.8	219
21	Metabolic phenotype of bladder cancer. <i>Cancer Treatment Reviews</i> , 2016, 45, 46-57.	8.1	215
22	2009 update on the classification of renal epithelial tumors in adults. <i>International Journal of Urology</i> , 2009, 16, 432-443.	1.3	214
23	Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 102.	9.0	211
24	Renal Cell Carcinoma in Tuberous Sclerosis Complex. <i>American Journal of Surgical Pathology</i> , 2014, 38, 895-909.	4.0	209
25	Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. <i>Human Pathology</i> , 2006, 37, 1371-1388.	2.4	208
26	Correlation of margin status and extraprostatic extension with progression of prostate carcinoma. <i>Cancer</i> , 1999, 86, 1775-1782.	4.1	204
27	Expression of PAX8 in Normal and Neoplastic Tissues. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2011, 19, 293-299.	1.3	200
28	Soil bio-cementation using a new one-phase low-pH injection method. <i>Acta Geotechnica</i> , 2019, 14, 615-626.	5.7	196
29	Evidence of Independent Origin of Multiple Tumors From Patients With Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 1998, 90, 233-237.	6.6	194
30	Small Cell Carcinoma of the Prostate: An Immunohistochemical Study. <i>American Journal of Surgical Pathology</i> , 2006, 30, 705-712.	4.0	192
31	Clear Cell Tubulopapillary Renal Cell Carcinoma: A Study of 36 Distinctive Low-grade Epithelial Tumors of the Kidney. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1608-1621.	4.0	189
32	Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocyoma. <i>Modern Pathology</i> , 2005, 18, 161-169.	5.8	186
33	Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. <i>Cancer</i> , 2004, 101, 83-89.	4.1	181
34	Molecular Genetic Evidence for a Common Clonal Origin of Urinary Bladder Small Cell Carcinoma and Coexisting Urothelial Carcinoma. <i>American Journal of Pathology</i> , 2005, 166, 1533-1539.	4.2	178
35	Arrhythmic Gut Microbiome Signatures Predict Risk of Type 2 Diabetes. <i>Cell Host and Microbe</i> , 2020, 28, 258-272.e6.	11.1	178
36	Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. <i>Cancers</i> , 2021, 13, 131.	3.9	178

#	ARTICLE	IF	CITATIONS
37	SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression. <i>Molecular Cell</i> , 2015, 59, 917-930.	9.7	175
38	Independent origin of multiple foci of prostatic intraepithelial neoplasia. <i>Cancer</i> , 1998, 83, 1995-2002.	4.1	174
39	Bladder cancer: translating molecular genetic insights into clinical practice. <i>Human Pathology</i> , 2011, 42, 455-481.	2.4	173
40	Staging and reporting of urothelial carcinoma of the urinary bladder. <i>Modern Pathology</i> , 2009, 22, S70-S95.	5.8	170
41	gutMDisorder: a comprehensive database for dysbiosis of the gut microbiota in disorders and interventions. <i>Nucleic Acids Research</i> , 2020, 48, D554-D560.	14.2	160
42	TFE3 Break-apart FISH Has a Higher Sensitivity for Xp11.2 Translocation-associated Renal Cell Carcinoma Compared With TFE3 or Cathepsin K Immunohistochemical Staining Alone. <i>American Journal of Surgical Pathology</i> , 2013, 37, 804-815.	4.0	159
43	LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling. <i>Nature Communications</i> , 2019, 10, 2571.	13.2	158
44	Construction and analysis of dysregulated lncRNA-associated ceRNA network identified novel lncRNA biomarkers for early diagnosis of human pancreatic cancer. <i>Oncotarget</i> , 2016, 7, 56383-56394.	1.8	157
45	Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. <i>Gut</i> , 2021, 70, 148-156.	13.9	157
46	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1392-1424.	5.8	156
47	Dysbiosis of the Gut Microbiome in Lung Cancer. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 112.	4.1	152
48	Survival of patients with carcinoma in situ of the urinary bladder. <i>Cancer</i> , 1999, 85, 2469-2474.	4.1	143
49	OCT4. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1341-1346.	4.0	143
50	Evidence for Common Clonal Origin of Multifocal Lung Cancers. <i>Journal of the National Cancer Institute</i> , 2009, 101, 560-570.	6.6	143
51	Natural History of Urothelial Dysplasia of the Bladder. <i>American Journal of Surgical Pathology</i> , 1999, 23, 443-447.	4.0	143
52	Expression of Group IIA Secretory Phospholipase A2 Is Elevated in Prostatic Intraepithelial Neoplasia and Adenocarcinoma. <i>American Journal of Pathology</i> , 2002, 160, 667-671.	4.2	142
53	Multivariate statistical differentiation of renal cell carcinomas based on lipidomic analysis by ambient ionization imaging mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 398, 2969-2978.	3.9	142
54	Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases. <i>Human Pathology</i> , 2005, 36, 718-723.	2.4	138

#	ARTICLE	IF	CITATIONS
55	Predicting the survival of bladder carcinoma patients treated with radical cystectomy. <i>Cancer</i> , 2000, 88, 2326-2332.	4.1	136
56	Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 295-314.	2.5	136
57	Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry. <i>Cancer</i> , 2004, 101, 2006-2010.	4.1	135
58	Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation. <i>Molecular Cell</i> , 2015, 59, 904-916.	9.7	133
59	Histologic Grading of Noninvasive Papillary Urothelial Neoplasms. <i>European Urology</i> , 2007, 51, 889-898.	5.1	132
60	Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. <i>Cancer</i> , 2000, 88, 1663-1670.	4.1	130
61	Diagnostic Utility of Novel Stem Cell Markers SALL4, OCT4, NANOG, SOX2, UTF1, and TCL1 in Primary Mediastinal Germ Cell Tumors. <i>American Journal of Surgical Pathology</i> , 2010, 34, 697-706.	4.0	130
62	ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. <i>Modern Pathology</i> , 2011, 24, 1120-1127.	5.8	130
63	Clear cell papillary renal cell carcinoma: differential diagnosis and extended immunohistochemical profile. <i>Modern Pathology</i> , 2013, 26, 697-708.	5.8	130
64	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1167-1184.	5.8	130
65	Predicting Cancer Progression in Patients With Stage T1 Bladder Carcinoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 3182-3187.	5.3	128
66	CYSTIC RENAL CELL CARCINOMA IS CURED BY RESECTION: A STUDY OF 24 CASES WITH LONG-TERM FOLLOWUP. <i>Journal of Urology</i> , 1999, 161, 408-411.	3.9	128
67	Renal mucinous tubular and spindle carcinoma lacks the gains of chromosomes 7 and 17 and losses of chromosome Y that are prevalent in papillary renal cell carcinoma. <i>Modern Pathology</i> , 2006, 19, 488-493.	5.8	127
68	Grading and Staging of Bladder Carcinoma in Transurethral Resection Specimens. <i>American Journal of Clinical Pathology</i> , 2000, 113, 275-279.	0.8	126
69	Variants and new entities of bladder cancer. <i>Histopathology</i> , 2019, 74, 77-96.	3.1	126
70	Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications. <i>Cells</i> , 2020, 9, 2653.	4.3	126
71	Overexpression of the wild type p73 gene in human bladder cancer. <i>Oncogene</i> , 1999, 18, 1629-1633.	5.9	125
72	Preoperative Prediction of Surgical Margin Status in Patients With Prostate Cancer Treated by Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2000, 18, 2862-2868.	5.3	125

#	ARTICLE	IF	CITATIONS
73	Inflammatory Pseudotumor and Sarcoma of Urinary Bladder: Differential Diagnosis and Outcome in Thirty-Eight Spindle Cell Neoplasms. <i>Modern Pathology</i> , 2001, 14, 1043-1051.	5.8	125
74	Gains of Chromosomes 7, 17, 12, 16, and 20 and Loss of Y Occur Early in the Evolution of Papillary Renal Cell Neoplasia: A Fluorescent In Situ Hybridization Study. <i>Modern Pathology</i> , 2003, 16, 1053-1059.	5.8	123
75	Staging of bladder cancer. <i>Histopathology</i> , 2019, 74, 112-134.	3.1	123
76	Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer. <i>Cancer</i> , 1999, 86, 1035-1043.	4.1	119
77	Cancer Volume of Lymph Node Metastasis Predicts Progression in Prostate Cancer. <i>American Journal of Surgical Pathology</i> , 1998, 22, 1491-1500.	4.0	119
78	Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1457-1472.	4.0	118
79	Staging of prostate cancer. <i>Histopathology</i> , 2012, 60, 87-117.	3.1	117
80	Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5â€%ml) in whole-mount prostatectomy specimens. <i>Modern Pathology</i> , 2005, 18, 1022-1026.	5.8	116
81	Interobserver Reproducibility in the Diagnosis of Invasive Micropapillary Carcinoma of the Urinary Tract Among Urologic Pathologists. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1367-1376.	4.0	115
82	Sarcomatoid Carcinoma of the Urinary Bladder. <i>American Journal of Surgical Pathology</i> , 2011, 35, e34-e46.	4.0	115
83	Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 10094-10099.	7.6	115
84	Villous Adenoma of the Urinary Tract: A Report of 23 Cases, Including 8 With Coexistent Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 1999, 23, 764.	4.0	115
85	Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformation. <i>Cancer</i> , 2005, 104, 1195-1203.	4.1	113
86	High-Level Expression of EphA2 Receptor Tyrosine Kinase in Prostatic Intraepithelial Neoplasia. <i>American Journal of Pathology</i> , 2003, 163, 2271-2276.	4.2	112
87	OCT4 Immunohistochemistry Is Superior to Placental Alkaline Phosphatase (PLAP) in the Diagnosis of Central Nervous System Germinoma. <i>American Journal of Surgical Pathology</i> , 2005, 29, 368-371.	4.0	112
88	DeepLGP: a novel deep learning method for prioritizing lncRNA target genes. <i>Bioinformatics</i> , 2020, 36, 4466-4472.	4.2	112
89	Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. <i>Modern Pathology</i> , 2015, 28, 612-630.	5.8	109
90	MetSigDis: a manually curated resource for the metabolic signatures of diseases. <i>Briefings in Bioinformatics</i> , 2019, 20, 203-209.	6.6	109

#	ARTICLE	IF	CITATIONS
91	Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. <i>Human Pathology</i> , 2009, 40, 10-29.	2.4	108
92	Paraganglioma of the urinary bladder. <i>Cancer</i> , 2000, 88, 844-852.	4.1	107
93	A hybrid type Ia supernova with an early flash triggered by helium-shell detonation. <i>Nature</i> , 2017, 550, 80-83.	36.3	107
94	OAHG: an integrated resource for annotating human genes with multi-level ontologies. <i>Scientific Reports</i> , 2016, 6, 34820.	3.5	106
95	LYMPHOVASCULAR INVASION IS AN INDEPENDENT PROGNOSTIC FACTOR IN PROSTATIC ADENOCARCINOMA. <i>Journal of Urology</i> , 2005, 174, 2181-2185.	3.9	105
96	Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 279-292.	4.0	105
97	Computational Methods for Identifying Similar Diseases. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 18, 590-604.	5.2	105
98	Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features. <i>Human Pathology</i> , 2008, 39, 96-101.	2.4	103
99	Plasmacytoid urothelial carcinoma of the bladder. <i>Human Pathology</i> , 2009, 40, 1023-1028.	2.4	103
100	Multilocular cystic renal cell carcinoma is a subtype of clear cell renal cell carcinoma. <i>Modern Pathology</i> , 2010, 23, 931-936.	5.8	103
101	Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 440, 3-11.	3.0	102
102	A potential prognostic long non-coding RNA signature to predict metastasis-free survival of breast cancer patients. <i>Scientific Reports</i> , 2015, 5, 16553.	3.5	102
103	Metanephric Adenoma Lacks the Gains of Chromosomes 7 and 17 and Loss of Y That Are Typical of Papillary Renal Cell Carcinoma and Papillary Adenoma. <i>Modern Pathology</i> , 2003, 16, 1060-1063.	5.8	101
104	Correcting the Shrinkage Effects of Formalin Fixation and Tissue Processing for Renal Tumors: toward Standardization of Pathological Reporting of Tumor Size. <i>Journal of Cancer</i> , 2015, 6, 759-766.	2.6	101
105	Renal Cell Carcinomas With Papillary Architecture and Clear Cell Components. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1780-1786.	4.0	100
106	Molecular genetic alterations in the laser-capture-microdissected stroma adjacent to bladder carcinoma. <i>Cancer</i> , 2003, 98, 1830-1836.	4.1	99
107	Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 547-557.	3.4	98
108	InfAcrOnt: calculating cross-ontology term similarities using information flow by a random walk. <i>BMC Genomics</i> , 2018, 19, 919.	2.9	98

#	ARTICLE	IF	CITATIONS
109	Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma. <i>Modern Pathology</i> , 2008, 21, 1-6.	5.8	97
110	Neuroendocrine tumours of the urinary system and male genital organs: clinical significance. <i>BJU International</i> , 2009, 103, 1464-1470.	2.8	96
111	Adrenal Myelolipomas Show Nonrandom X-chromosome Inactivation in Hematopoietic Elements and Fat: Support for a Clonal Origin of Myelolipomas. <i>American Journal of Surgical Pathology</i> , 2006, 30, 838-843.	4.0	95
112	Selective recovery of valuable metals from industrial waste lithium-ion batteries using citric acid under reductive conditions: Leaching optimization and kinetic analysis. <i>Hydrometallurgy</i> , 2020, 191, 105160.	4.5	95
113	Papillary urothelial neoplasms of low malignant potential. <i>Cancer</i> , 1999, 86, 2102-2108.	4.1	94
114	Tertiary Gleason Pattern 5 is a Powerful Predictor of Biochemical Relapse in Patients With Gleason Score 7 Prostatic Adenocarcinoma. <i>Journal of Urology</i> , 2006, 175, 1695-1699.	3.9	94
115	Soft tissue tumors of the urinary bladder, part I: myofibroblastic proliferations, benign neoplasms, and tumors of uncertain malignant potential. <i>Human Pathology</i> , 2007, 38, 807-823.	2.4	94
116	Acquired cystic disease-associated renal tumors: an immunohistochemical and fluorescence in situ hybridization study. <i>Modern Pathology</i> , 2006, 19, 780-787.	5.8	92
117	Electroencephalography-based motor imagery classification using temporal convolutional network fusion. <i>Biomedical Signal Processing and Control</i> , 2021, 69, 102826.	5.9	92
118	Lymphoepithelioma-like Carcinoma of the Urinary Bladder. <i>American Journal of Surgical Pathology</i> , 2011, 35, 474-483.	4.0	91
119	The Combined Percentage of Gleason Patterns 4 and 5 Is the Best Predictor of Cancer Progression After Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2005, 23, 2911-2917.	5.3	90
120	Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. <i>Human Pathology</i> , 2017, 63, 149-156.	2.4	90
121	gutMGene: a comprehensive database for target genes of gut microbes and microbial metabolites. <i>Nucleic Acids Research</i> , 2022, 50, D795-D800.	14.2	90
122	Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. <i>Human Pathology</i> , 2010, 41, 155-162.	2.4	89
123	Renal Cell Carcinomas With t(6;11)(p21;q12). <i>American Journal of Surgical Pathology</i> , 2012, 36, 1327-1338.	4.0	88
124	Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers. <i>Modern Pathology</i> , 2013, 26, 725-732.	5.8	88
125	Biomarkers in bladder cancer: Translational and clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 73-111.	4.6	88
126	<i>BAP1</i> , <i>PBRM1</i> and <i>SETD2</i> in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1201-1210.	3.4	88



#	ARTICLE	IF	CITATIONS
127	Flat intraepithelial lesions of the urinary bladder. <i>Cancer</i> , 2000, 88, 625-631.	4.1	87
128	Neuroendocrine Expression in Node Positive Prostate Cancer: Correlation With Systemic Progression and Patient Survival. <i>Journal of Urology</i> , 2002, 168, 1204-1211.	3.9	87
129	Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. <i>Histopathology</i> , 2016, 69, 441-449.	3.1	87
130	Precursors of prostate cancer. <i>Histopathology</i> , 2012, 60, 4-27.	3.1	86
131	Expression of Alpha-Methylacyl-Coenzyme A Racemase in Nephrogenic Adenoma. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1224-1229.	4.0	85
132	<i>KIT</i> gene mutation and amplification in dysgerminoma of the ovary. <i>Cancer</i> , 2011, 117, 2096-2103.	4.1	85
133	PD-L1 assessment in urothelial carcinoma: a practical approach. <i>Annals of Translational Medicine</i> , 2019, 7, 690-690.	1.7	85
134	Tumor size predicts the survival of patients with pathologic stage t2 bladder carcinoma. <i>Cancer</i> , 1999, 85, 2638-2647.	4.1	84
135	Papillary Urothelial Neoplasm of Low Malignant Potential: Evolving Terminology and Concepts. <i>Journal of Urology</i> , 2006, 175, 1995-2003.	3.9	84
136	Divergent pathway of intestinal metaplasia and cystitis glandularis of the urinary bladder. <i>Modern Pathology</i> , 2006, 19, 1395-1401.	5.8	84
137	Inflammatory Myofibroblastic Tumors of the Genitourinary Tract—Single Entity or Continuum?. <i>Journal of Urology</i> , 2008, 180, 1235-1240.	3.9	84
138	Prognostic and Therapeutic Impact of the Histopathologic Definition of Parenchymal Epithelial Renal Tumors. <i>European Urology</i> , 2010, 58, 655-668.	5.1	84
139	Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer. <i>Modern Pathology</i> , 2005, 18, 886-890.	5.8	83
140	Urothelial Carcinoma With an Inverted Growth Pattern Can be Distinguished From Inverted Papilloma by Fluorescence In Situ Hybridization, Immunohistochemistry, and Morphologic Analysis. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1861-1867.	4.0	83
141	Particle Bombardment-Mediated Gene Transfer and Expression in Rat Brain Tissues. <i>Nature Biotechnology</i> , 1993, 11, 497-502.	21.0	82
142	DIAGNOSIS AND GRADING OF BLADDER CANCER AND ASSOCIATED LESIONS. <i>Urologic Clinics of North America</i> , 1999, 26, 493-507.	2.0	82
143	Identical Allelic Losses in Mature Teratoma and Other Histologic Components of Malignant Mixed Germ Cell Tumors of the Testis. <i>American Journal of Pathology</i> , 2003, 163, 2477-2484.	4.2	81
144	Histologic grading of urothelial carcinoma: a reappraisal. <i>Human Pathology</i> , 2012, 43, 2097-2108.	2.4	81

#	ARTICLE	IF	CITATIONS
145	Contemporary bladder cancer: Variant histology may be a significant driver of disease. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 18.e15-18.e20.	1.8	81
146	Diagnosis of Prostate Cancer in Needle Biopsies After Radiation Therapy. <i>American Journal of Surgical Pathology</i> , 1999, 23, 1173.	4.0	81
147	Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor. <i>Cancer</i> , 2002, 94, 104-110.	4.1	80
148	Soft tissue tumors of the urinary bladder. <i>Human Pathology</i> , 2007, 38, 963-977.	2.4	80
149	Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. <i>Endocrine-Related Cancer</i> , 2012, 19, 321-331.	3.4	80
150	Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 29720-29738.	1.8	80
151	Molecular Genetic Evidence for Different Clonal Origin of Components of Human Renal Angiomyolipomas. <i>American Journal of Surgical Pathology</i> , 2001, 25, 1231-1236.	4.0	79
152	Natural history of urothelial inverted papilloma. <i>Cancer</i> , 2006, 107, 2622-2627.	4.1	78
153	Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms (<sc>PEC</sc>omas): a clinicopathological study emphasizing extrarenal <sc>PEC</sc>omas. <i>Histopathology</i> , 2013, 62, 642-650.	3.1	78
154	Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 111-117.	3.9	78
155	Overexpression of Pea DNA Helicase 45 (PDH45) imparts tolerance to multiple abiotic stresses in chili ( <i>Capsicum annuum</i> L.). <i>Scientific Reports</i> , 2017, 7, 2760.	3.5	78
156	Movement Disorder Society Task Force Viewpoint: Huntington's Disease Diagnostic Categories. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 541-546.	1.7	78
157	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. <i>Cancers</i> , 2020, 12, 1449.	3.9	78
158	Fluorescence in situ hybridization analysis of chromosome 12p in paraffin-embedded tissue is useful for establishing germ cell origin of metastatic tumors. <i>Modern Pathology</i> , 2004, 17, 1309-1313.	5.8	77
159	Multilocular Cystic Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1425-1433.	4.0	77
160	Immune checkpoint inhibitors for metastatic bladder cancer. <i>Cancer Treatment Reviews</i> , 2018, 64, 11-20.	8.1	77
161	Endometrial Glandular Dysplasia: A Putative Precursor Lesion of Uterine Papillary Serous Carcinoma. Part II: Molecular Features. <i>International Journal of Surgical Pathology</i> , 2004, 12, 319-331.	0.9	76
162	Does pT2b prostate carcinoma exist? Critical appraisal of the 2002 TNM classification of prostate carcinoma. <i>Cancer</i> , 2004, 100, 2573-2576.	4.1	76

#	ARTICLE	IF	CITATIONS
163	Laser capture microdissection analysis reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder. <i>Cancer</i> , 2004, 101, 183-188.	4.1	76
164	Analysis of ovarian teratomas for isochromosome 12p: evidence supporting a dual histogenetic pathway for teratomatous elements. <i>Modern Pathology</i> , 2006, 19, 766-771.	5.8	76
165	Chromosomal gains in the sarcomatoid transformation of chromophobe renal cell carcinoma. <i>Modern Pathology</i> , 2007, 20, 303-309.	5.8	76
166	Diagnosis and Management of Urothelial Carcinoma In Situ of the Lower Urinary Tract: A Systematic Review. <i>European Urology</i> , 2015, 67, 876-888.	5.1	76
167	Exposing the Causal Effect of C-Reactive Protein on the Risk of Type 2 Diabetes Mellitus: A Mendelian Randomization Study. <i>Frontiers in Genetics</i> , 2018, 9, 657.	2.4	76
168	c-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications. <i>Modern Pathology</i> , 2005, 18, 320-323.	5.8	75
169	Chromosome 12p abnormalities in dysgerminoma of the ovary: a FISH analysis. <i>Modern Pathology</i> , 2006, 19, 611-615.	5.8	75
170	Radial Distance of Extraprostatic Extension Measured by Ocular Micrometer is an Independent Predictor of Prostate-specific Antigen Recurrence. <i>American Journal of Surgical Pathology</i> , 2007, 31, 311-318.	4.0	75
171	Mechanisms of Disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate. <i>Nature Reviews Urology</i> , 2007, 4, 321-332.	0.8	75
172	Secondary neoplasms of the urinary system and male genital organs. <i>BJU International</i> , 2009, 104, 770-776.	2.8	75
173	The origins of urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 865-880.	2.5	74
174	p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma. <i>Modern Pathology</i> , 2012, 25, 1526-1533.	5.8	74
175	Malignant Perivascular Epithelioid Cell Neoplasm (PEComa) of the Urinary Bladder With TFE3 Gene Rearrangement. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1619-1626.	4.0	74
176	Metabolic alterations in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2015, 41, 767-776.	8.1	74
177	Cytokeratin 7 and Cytokeratin 20 in Primary Urinary Bladder Carcinoma and Matched Lymph Node Metastasis. <i>Archives of Pathology and Laboratory Medicine</i> , 2001, 125, 921-923.	2.6	74
178	Neurofibroma of the urinary bladder. <i>Cancer</i> , 1999, 86, 505-513.	4.1	73
179	Predicting Tumor Volume in Radical Prostatectomy Specimens From Patients With Prostate Cancer. <i>American Journal of Clinical Pathology</i> , 2003, 120, 386-391.	0.8	73
180	Primary Mediastinal Seminoma: A Comprehensive Assessment Integrated With Histology, Immunohistochemistry, and Fluorescence In Situ Hybridization for Chromosome 12p Abnormalities in 23 Cases. <i>American Journal of Surgical Pathology</i> , 2008, 32, 146-155.	4.0	73

#	ARTICLE	IF	CITATIONS
181	In vitro and in vivo evaluation of praziquantel loaded implants based on PEG/PCL blends. International Journal of Pharmaceutics, 2010, 387, 129-138.	5.4	73
182	Invasive micropapillary urothelial carcinoma of the bladder. Human Pathology, 2010, 41, 1159-1164.	2.4	73
183	Papillary Renal Neoplasm With Reverse Polarity. American Journal of Surgical Pathology, 2019, 43, 1099-1111.	4.0	73
184	Enhanced biodegradation of hydrophobic organic pollutants by the bacterial consortium: Impact of enzymes and biosurfactants. Environmental Pollution, 2021, 289, 117956.	7.7	73
185	Predictors of survival for prostate carcinoma patients treated with salvage radical prostatectomy after radiation therapy. Cancer, 1998, 83, 2164-2171.	4.1	72
186	Hemangioma of the urinary bladder. Cancer, 1999, 86, 498-504.	4.1	72
187	The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens. Human Pathology, 2007, 38, 1207-1211.	2.4	72
188	Evidence Supporting the Existence of Benign Teratomas of the Postpubertal Testis. American Journal of Surgical Pathology, 2013, 37, 827-835.	4.0	72
189	CD44 expression is a feature of prostatic small cell Carcinoma and Distinguishes it from its Mimickers. Human Pathology, 2009, 40, 252-258.	2.4	71
190	A Highly <i>syn</i> -selective Nitroaldol Reaction Catalyzed by Cu <sup>II</sup> -Bisimidazoline. Chemistry - A European Journal, 2010, 16, 6761-6765.	3.9	71
191	Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 199-205.	3.0	71
192	TP53 mutational analysis supports monoclonal origin of biphasic sarcomatoid urothelial carcinoma (carcinosarcoma) of the urinary bladder. Modern Pathology, 2009, 22, 113-118.	5.8	70
193	Clear Cell Papillary Renal Cell Carcinoma-like Tumors in Patients With Von Hippel-Lindau Disease Are Unrelated to Sporadic Clear Cell Papillary Renal Cell Carcinoma. American Journal of Surgical Pathology, 2013, 37, 1131-1139.	4.0	70
194	Is There a Role for Immunotherapy in Prostate Cancer?. Cells, 2020, 9, 2051.	4.3	70
195	Atypical nephrogenic metaplasia of the urinary tract. Cancer, 2000, 88, 853-861.	4.1	69
196	Birth Outcomes Among Adolescent and Young Adult Cancer Survivors. JAMA Oncology, 2017, 3, 1078.	7.4	69
197	Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs in Context, 2018, 7, 1-8.	2.6	69
198	A new survival model based on ferroptosis-related genes for prognostic prediction in clear cell renal cell carcinoma. Aging, 2020, 12, 14933-14948.	3.0	69

#	ARTICLE	IF	CITATIONS
199	Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: diagnostic and therapeutic implications. <i>Modern Pathology</i> , 2005, 18, 1411-1416.	5.8	68
200	Diagnosis of "Poorly Formed Glands" Gleason Pattern 4 Prostatic Adenocarcinoma on Needle Biopsy. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1331-1339.	4.0	68
201	Predicting Cancer Progression in Patients with Penile Squamous Cell Carcinoma: The Importance of Depth of Invasion and Vascular Invasion. <i>Modern Pathology</i> , 2001, 14, 963-968.	5.8	67
202	Plasmacytoid Bladder Cancer: Variant Histology With Aggressive Behavior and a New Mode of Invasion Along Fascial Planes. <i>Urology</i> , 2014, 83, 1112-1116.	1.4	67
203	A potential panel of six-long non-coding RNA signature to improve survival prediction of diffuse large-B-cell lymphoma. <i>Scientific Reports</i> , 2016, 6, 27842.	3.5	66
204	Pathology and Genetics: Tumours of the Urinary System and Male Genital System. <i>European Urology</i> , 2016, 70, 120-123.	5.1	66
205	Drops and fibers " how biomolecular condensates and cytoskeletal filaments influence each other. <i>Emerging Topics in Life Sciences</i> , 2020, 4, 247-261.	2.6	66
206	Urothelial Carcinoma of the Bladder, Lipid Cell Variant: Clinicopathologic Findings and LOH Analysis. <i>American Journal of Surgical Pathology</i> , 2010, 34, 371-376.	4.0	65
207	Glandular lesions of the urinary bladder: clinical significance and differential diagnosis. <i>Histopathology</i> , 2011, 58, 811-834.	3.1	65
208	Feasibility of Omitting Cortical Renorrhaphy During Robot-Assisted Partial Nephrectomy: A Matched Analysis. <i>Journal of Endourology</i> , 2015, 29, 548-555.	2.3	65
209	Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification. <i>Endocrine Pathology</i> , 2016, 27, 123-135.	10.4	65
210	Closest Distance Between Tumor and Resection Margin in Radical Prostatectomy Specimens. <i>American Journal of Surgical Pathology</i> , 2005, 29, 225-229.	4.0	63
211	OCT4 is superior to CD30 in the diagnosis of metastatic embryonal carcinomas after chemotherapy. <i>Human Pathology</i> , 2006, 37, 662-667.	2.4	63
212	Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy. <i>Cancer</i> , 2007, 110, 1967-1972.	4.1	63
213	Primitive neuroectodermal tumors in patients with testicular germ cell tumors usually resemble pediatric-type central nervous system embryonal neoplasms and lack chromosome 22 rearrangements. <i>Modern Pathology</i> , 2010, 23, 972-980.	5.8	63
214	Laser-assisted Microdissection in Translational Research. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 31-47.	1.3	63
215	Computational and Biological Methods for Gene Therapy. <i>Current Gene Therapy</i> , 2019, 19, 210-210.	2.1	63
216	Loss of expression of the SWI/SNF complex is a frequent event in undifferentiated/dedifferentiated urothelial carcinoma of the urinary tract. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 321-330.	3.0	62

#	ARTICLE	IF	CITATIONS
217	Molecular Genetic Evidence Supporting the Origin of Somatic-type Malignancy and Teratoma From the Same Progenitor Cell. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1849-1856.	4.0	61
218	Renal Cell Carcinoma With Chromosome 6p Amplification Including the TFEB Gene. <i>American Journal of Surgical Pathology</i> , 2017, 41, 287-298.	4.0	61
219	A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157. <i>Clinical Cancer Research</i> , 2017, 23, 3003-3011.	7.3	61
220	Urothelial papilloma of the bladder. <i>Cancer</i> , 1999, 86, 2098-2101.	4.1	60
221	Preoperative prediction of Gleason grade in radical prostatectomy specimens: the influence of different Gleason grades from multiple positive biopsy sites. <i>Modern Pathology</i> , 2005, 18, 228-234.	5.8	60
222	Rare and unusual histological variants of prostatic carcinoma: clinical significance. <i>BJU International</i> , 2008, 102, 1369-1374.	2.8	60
223	Ureteral endometriosis: clinicopathological and immunohistochemical study of 7 cases. <i>Human Pathology</i> , 2008, 39, 954-959.	2.4	60
224	Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance. <i>Npj Precision Oncology</i> , 2022, 6, 31.	5.5	60
225	p53 Protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. <i>Cancer</i> , 1999, 85, 1293-1299.	4.1	59
226	Stage pT1 bladder carcinoma: diagnostic criteria, pitfalls and prognostic significance. <i>Pathology</i> , 2003, 35, 484-491.	0.7	59
227	Inverted papilloma of the urinary bladder: a molecular genetic appraisal. <i>Modern Pathology</i> , 2006, 19, 1289-1294.	5.8	59
228	Do Clear Cell Papillary Renal Cell Carcinomas Have Malignant Potential?. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1621-1634.	4.0	59
229	Role of STAT3 pathway in genitourinary tumors. <i>Future Science OA</i> , 2015, 1, FSO15.	2.0	59
230	Different prognostic roles of tumor suppressor gene <i>BAP1</i> in cancer: A systematic review with meta-analysis. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 741-749.	3.4	59
231	Rhabdoid and Undifferentiated Phenotype in Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2017, 41, 253-262.	4.0	59
232	Integrative Analysis of Pathological Images and Multi-Dimensional Genomic Data for Early-Stage Cancer Prognosis. <i>IEEE Transactions on Medical Imaging</i> , 2020, 39, 99-110.	9.2	59
233	Molecular Genetic Evidence for Different Clonal Origins of Epithelial and Stromal Components of Phyllodes Tumor of the Prostate. <i>American Journal of Pathology</i> , 2004, 165, 1395-1400.	4.2	58
234	Characterization and in vitro release of praziquantel from poly( $\epsilon$ -caprolactone) implants. <i>International Journal of Pharmaceutics</i> , 2009, 377, 112-119.	5.4	58

#	ARTICLE	IF	CITATIONS
235	Renal Cell Neoplasms of Oncocytosis Have Distinct Morphologic, Immunohistochemical, and Cytogenetic Profiles. <i>American Journal of Surgical Pathology</i> , 2010, 34, 620-626.	4.0	58
236	Polo-like Kinase 1 Facilitates Loss of Pten Tumor Suppressor-induced Prostate Cancer Formation. <i>Journal of Biological Chemistry</i> , 2011, 286, 35795-35800.	3.5	58
237	gutMDisorder: a comprehensive database for dysbiosis of the gut microbiota in disorders and interventions. <i>Nucleic Acids Research</i> , 2020, 48, 7603.	14.2	58
238	Extranodal Extension in Lymph Node-Positive Prostate Cancer. <i>Modern Pathology</i> , 2000, 13, 113-118.	5.8	57
239	Nephroblastoma Arising in a Germ Cell Tumor of Testicular Origin. <i>American Journal of Surgical Pathology</i> , 2004, 28, 687-692.	4.0	57
240	Is Incidentally Detected Prostate Cancer in Patients Undergoing Radical Cystoprostatectomy Clinically Significant?. <i>American Journal of Clinical Pathology</i> , 2009, 131, 279-283.	0.8	57
241	Biologically reduced graphene oxide as a green and easily available photocatalyst for degradation of organic dyes. <i>Environmental Research</i> , 2021, 196, 110983.	7.7	57
242	Squamous papilloma of the urinary tract is unrelated to condyloma acuminata. <i>Cancer</i> , 2000, 88, 1679-1686.	4.1	56
243	Bladder neck invasion is an independent predictor of prostate-specific antigen recurrence. <i>Cancer</i> , 2004, 101, 1563-1568.	4.1	56
244	PERINEURAL INVASION IN RADICAL PROSTATECTOMY SPECIMENS: LACK OF PROGNOSTIC SIGNIFICANCE. <i>Journal of Urology</i> , 2004, 172, 2249-2251.	3.9	56
245	Genetically Heterogeneous and Clonally Unrelated Metastases May Arise in Patients With Cutaneous Melanoma. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1029-1037.	4.0	56
246	Clear Cell Renal Cell Carcinoma With Borderline Features of Clear Cell Papillary Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1502-1510.	4.0	56
247	Metanephric adenoma: the utility of immunohistochemical and cytogenetic analyses in differential diagnosis, including solid variant papillary renal cell carcinoma and epithelial-predominant nephroblastoma. <i>Modern Pathology</i> , 2015, 28, 1236-1248.	5.8	56
248	Perspectives on testicular germ cell neoplasms. <i>Human Pathology</i> , 2017, 59, 10-25.	2.4	56
249	Exposing the Causal Effect of Body Mass Index on the Risk of Type 2 Diabetes Mellitus: A Mendelian Randomization Study. <i>Frontiers in Genetics</i> , 2019, 10, 94.	2.4	56
250	Identifying diseases-related metabolites using random walk. <i>BMC Bioinformatics</i> , 2018, 19, 116.	2.7	55
251	Renal cell carcinoma staging: pitfalls, challenges, and updates. <i>Histopathology</i> , 2019, 74, 18-30.	3.1	55
252	The relationship between gut microbiota and short chain fatty acids in the renal calcium oxalate stones disease. <i>FASEB Journal</i> , 2020, 34, 11200-11214.	0.5	55



#	ARTICLE	IF	CITATIONS
253	Clinical Utility of Immunohistochemistry in the Diagnoses of Urinary Bladder Neoplasia. Applied Immunohistochemistry and Molecular Morphology, 2010, 18, 401-410.	1.3	55
254	Dedifferentiation in the metastatic progression of prostate carcinoma. Cancer, 1999, 86, 657-663.	4.1	54
255	Anatomic distribution of periprostatic adipose tissue. Cancer, 2003, 97, 1639-1643.	4.1	54
256	Small Cell Carcinoma of the Urinary Bladder—Histogenesis, Genetics, Diagnosis, Biomarkers, Treatment, and Prognosis. Applied Immunohistochemistry and Molecular Morphology, 2007, 15, 8-18.	1.3	54
257	Microcystic urothelial carcinoma: morphology, immunohistochemistry and clinical behaviour. Histopathology, 2014, 64, 872-879.	3.1	54
258	Plasmacytoid variant urothelial bladder cancer: Is it time to update the treatment paradigm? Contributed equally to manuscript.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 833-838.	1.8	54
259	Telomerase reverse transcriptase (<sc>TERT</sc>) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change. Histopathology, 2016, 69, 107-113.	3.1	54
260	DisSim: an online system for exploring significant similar diseases and exhibiting potential therapeutic drugs. Scientific Reports, 2016, 6, 30024.	3.5	54
261	Urethral caruncle: clinicopathologic features of 41 cases. Human Pathology, 2012, 43, 1400-1404.	2.4	53
262	Computational analysis of pathological images enables a better diagnosis of TFE3 Xp11.2 translocation renal cell carcinoma. Nature Communications, 2020, 11, 1778.	13.2	53
263	Efficient persistent organic pollutant removal in water using MIL-metal—organic framework driven Fenton-like reactions: A critical review. Chemical Engineering Journal, 2022, 431, 134182.	13.0	53
264	Allelic imbalance in the clonal evolution of prostate carcinoma. Cancer, 1999, 85, 2017-2022.	4.1	52
265	Prostate needle biopsies. Cancer, 2004, 101, 527-532.	4.1	52
266	Pleomorphic giant cell carcinoma of the urinary bladder. Human Pathology, 2009, 40, 1461-1466.	2.4	52
267	Neuroendocrine Tumors of the Urinary Bladder According to the 2016 World Health Organization Classification: Molecular and Clinical Characteristics. Endocrine Pathology, 2016, 27, 188-199.	10.4	52
268	IntNetLncSim: an integrative network analysis method to infer human lncRNA functional similarity. Oncotarget, 2016, 7, 47864-47874.	1.8	52
269	Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone. Human Pathology, 2017, 65, 239-246.	2.4	51
270	Measuring disease similarity and predicting disease-related ncRNAs by a novel method. BMC Medical Genomics, 2017, 10, 71.	1.6	51



#	ARTICLE	IF	CITATIONS
271	Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation. <i>Pathology</i> , 2019, 51, 463-473.	0.7	51
272	Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity. <i>Modern Pathology</i> , 2020, 33, 1157-1164.	5.8	51
273	Bio-mediated soil improvement: An introspection into processes, materials, characterization and applications. <i>Soil Use and Management</i> , 2022, 38, 68-93.	4.6	51
274	Renal cell carcinoma with angioleiomyoma-like stroma: clinicopathological, immunohistochemical, and molecular features supporting classification as a distinct entity. <i>Modern Pathology</i> , 2015, 28, 279-294.	5.8	50
275	Grading of prostate cancer: a work in progress. <i>Histopathology</i> , 2019, 74, 146-160.	3.1	50
276	psSubpathway: a software package for flexible identification of phenotype-specific subpathways in cancer progression. <i>Bioinformatics</i> , 2020, 36, 2303-2305.	4.2	50
277	Cystic Trophoblastic Tumor. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1212-1216.	4.0	49
278	PREOPERATIVE PREDICTION OF SMALL VOLUME CANCER (LESS THAN 0.5 ML) IN RADICAL PROSTATECTOMY SPECIMENS. <i>Journal of Urology</i> , 2005, 174, 898-902.	3.9	49
279	The spectrum of histopathologic findings in vesical diverticulum: implications for pathogenesis and staging. <i>Human Pathology</i> , 2013, 44, 1223-1232.	2.4	49
280	PAX8 Mouse Monoclonal Antibody [BC12] Recognizes a Restricted Epitope and Is Highly Sensitive in Renal Cell and Ovarian Cancers But Does Not Cross-react With B Cells and Tumors of Pancreatic Origin. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 59-63.	1.3	49
281	The role of polytherapy in the management of epilepsy: suggestions for rational antiepileptic drug selection. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 167-173.	2.9	49
282	Morphologic, immunohistochemical, and fluorescence in situ hybridization study of ovarian embryonal carcinoma with comparison to solid variant of yolk sac tumor and immature teratoma. <i>Human Pathology</i> , 2010, 41, 716-723.	2.4	48
283	The Landscape of <i>EGFR</i> Pathways and Personalized Management of Non-Small-Cell Lung Cancer. <i>Future Oncology</i> , 2011, 7, 519-541.	2.4	48
284	Predicting disease-related genes using integrated biomedical networks. <i>BMC Genomics</i> , 2017, 18, 1043.	2.9	48
285	Prognostic Role of High-Grade Tumor Budding in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis with a Focus on Epithelial to Mesenchymal Transition. <i>Cancers</i> , 2019, 11, 113.	3.9	48
286	Adrenergic stress constrains the development of anti-tumor immunity and abscopal responses following local radiation. <i>Nature Communications</i> , 2020, 11, 1821.	13.2	48
287	Pathological variants of invasive bladder cancer according to their suggested clinical significance. <i>BJU International</i> , 2008, 101, 275-281.	2.8	47
288	FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations. <i>Modern Pathology</i> , 2009, 22, 627-632.	5.8	47

#	ARTICLE	IF	CITATIONS
289	Modelling farm-to-farm disease transmission through personnel movements: from visits to contacts, and back. <i>Scientific Reports</i> , 2017, 7, 2375.	3.5	47
290	Human Disease System Biology. <i>Current Gene Therapy</i> , 2018, 18, 255-256.	2.1	47
291	PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications. <i>Human Pathology</i> , 2018, 81, 157-165.	2.4	47
292	A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2021, 80, 712-723.	5.1	47
293	Recent Advances of Deep Learning for Computational Histopathology: Principles and Applications. <i>Cancers</i> , 2022, 14, 1199.	3.9	47
294	Original Gleason System Versus 2005 ISUP Modified Gleason System: The Importance of Indicating Which System Is Used in the Patient's Pathology and Clinical Reports. <i>European Urology</i> , 2010, 58, 369-373.	5.1	46
295	Prevalence and Distribution of Prostatic Intraepithelial Neoplasia in Salvage Radical Prostatectomy Specimens After Radiation Therapy. <i>American Journal of Surgical Pathology</i> , 1999, 23, 803.	4.0	46
296	Inverted urothelial papilloma. <i>Cancer</i> , 2000, 88, 632-636.	4.1	45
297	Molecular Determinants of Tumor Recurrence in The Urinary Bladder. <i>Future Oncology</i> , 2009, 5, 843-857.	2.4	45
298	Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: The state of the art. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 76, 112-126.	4.6	45
299	Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry. <i>Human Pathology</i> , 2013, 44, 2227-2233.	2.4	45
300	Uroplakin II (UPII), GATA3, and p40 are Highly Sensitive Markers for the Differential Diagnosis of Invasive Urothelial Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015, 23, 711-716.	1.3	45
301	Clonal origin of lymph node metastases in bladder carcinoma. <i>Cancer</i> , 2005, 104, 1901-1910.	4.1	44
302	The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders. <i>Modern Pathology</i> , 2007, 20, 929-935.	5.8	44
303	Emerging Critical Role of Molecular Testing in Diagnostic Genitourinary Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 372-390.	2.6	44
304	Morphological spectrum of renal cell carcinoma, unclassified: an analysis of 136 cases. <i>Histopathology</i> , 2018, 72, 305-319.	3.1	44
305	Histopathological findings after treatment of prostate cancer using high-intensity focused ultrasound (HIFU). <i>Prostate</i> , 2010, 70, 1196-1200.	2.3	43
306	Molecular pathology of malignant melanoma: changing the clinical practice paradigm toward a personalized approach. <i>Human Pathology</i> , 2014, 45, 1315-1326.	2.4	43

#	ARTICLE	IF	CITATIONS
307	Ambient ionization mass spectrometric analysis of human surgical specimens to distinguish renal cell carcinoma from healthy renal tissue. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 5407-5414.	3.9	43
308	GAB2 rs2373115 variant contributes to Alzheimer's disease risk specifically in European population. <i>Journal of the Neurological Sciences</i> , 2017, 375, 18-22.	0.6	43
309	Anti-LOX-1 therapy in rats with diabetes and dyslipidemia: ablation of renal vascular and epithelial manifestations. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 294, F110-F119.	3.0	42
310	Urothelial lesions with inverted growth patterns: histogenesis, molecular genetic findings, differential diagnosis and clinical management. <i>BJU International</i> , 2011, 107, 532-537.	2.8	42
311	Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists. <i>Annals of Diagnostic Pathology</i> , 2014, 18, 333-342.	1.4	42
312	Extranodal Extension of Nodal Metastases Is a Poor Prognostic Indicator in Gastric Cancer: a Systematic Review and Meta-analysis. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1692-1698.	2.1	42
313	The Identification of Immunological Biomarkers in Kidney Cancers. <i>Frontiers in Oncology</i> , 2018, 8, 456.	3.0	42
314	Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype. <i>Human Pathology</i> , 2018, 80, 55-64.	2.4	42
315	Identification of Alzheimer's Disease-Related Genes Based on Data Integration Method. <i>Frontiers in Genetics</i> , 2018, 9, 703.	2.4	42
316	Report From the International Society of Urological Pathology (ISUP) Consultation Conference On Molecular Pathology Of Urogenital Cancers. II. Molecular Pathology of Bladder Cancer. <i>American Journal of Surgical Pathology</i> , 2020, 44, e30-e46.	4.0	42
317	Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. <i>Cancer</i> , 2008, 112, 636-644.	4.1	41
318	Tubulocystic carcinoma of the kidney with poorly differentiated foci: a series of 3 cases with fluorescence in situ hybridization analysis. <i>Human Pathology</i> , 2013, 44, 1406-1411.	2.4	41
319	Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists. <i>Histopathology</i> , 2014, 65, 216-227.	3.1	41
320	Application of Molecular Diagnostic Techniques to Renal Epithelial Neoplasms. <i>Clinics in Laboratory Medicine</i> , 2005, 25, 279-303.	1.3	40
321	Cytokeratin and CD30 expression in dysgerminoma. <i>Human Pathology</i> , 2006, 37, 1015-1021.	2.4	40
322	Urothelial carcinoma following augmentation cystoplasty: an aggressive variant with distinct clinicopathological characteristics and molecular genetic alterations. <i>Histopathology</i> , 2009, 55, 161-173.	3.1	40
323	Clear cell renal cell carcinoma with a syncytial-type multinucleated giant tumor cell component: implications for differential diagnosis. <i>Human Pathology</i> , 2014, 45, 735-744.	2.4	40
324	Neuroendocrine differentiation in prostate cancer: Novel morphological insights and future therapeutic perspectives. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 630-637.	7.7	40

#	ARTICLE	IF	CITATIONS
325	Enhanced coproduction of hydrogen and butanol from rice straw by a novel two-stage fermentation process. <i>International Biodeterioration and Biodegradation</i> , 2018, 127, 62-68.	4.0	40
326	Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. <i>Cells</i> , 2019, 8, 43.	4.3	40
327	Î±-methylacyl-CoA racemase (P504S)/34Î²E12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy. <i>Human Pathology</i> , 2007, 38, 332-341.	2.4	39
328	Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-Îµmedullary thyroid carcinoma. <i>International Journal of Cancer</i> , 2019, 144, 1321-1330.	5.4	39
329	A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 294-301.	6.2	39
330	p53 Alteration in regional lymph node metastases from prostate carcinoma. <i>Cancer</i> , 1999, 85, 2455-2459.	4.1	38
331	Flat urothelial carcinoma in situ of the bladder with glandular differentiation. <i>Human Pathology</i> , 2011, 42, 1653-1659.	2.4	38
332	PAX8 is expressed in the majority of renal epithelial neoplasms: an immunohistochemical study of 223 cases using a mouse monoclonal antibody. <i>Journal of Clinical Pathology</i> , 2012, 65, 254-256.	2.2	38
333	Unclassified renal cell carcinoma: a report of 56 cases. <i>BJU International</i> , 2012, 110, 786-793.	2.8	38
334	Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy. <i>Modern Pathology</i> , 2015, 28, 480-486.	5.8	38
335	Peristomal skin complications: what dermatologists need to know. <i>International Journal of Dermatology</i> , 2018, 57, 257-264.	1.0	38
336	Persistent organic pollutant emission via dust deposition throughout Pakistan: Spatial patterns, regional cycling and their implication for human health risks. <i>Science of the Total Environment</i> , 2018, 618, 829-837.	8.2	38
337	Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 445-455.	3.0	38
338	Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis. <i>BMC Cancer</i> , 2019, 19, 232.	2.6	38
339	The Human Microbiota and Prostate Cancer: Friend or Foe?. <i>Cancers</i> , 2019, 11, 459.	3.9	38
340	The (In)Appropriateness of the WAR Metaphor in Response to SARS-CoV-2: A Rapid Analysis of Donald J. Trump's Rhetoric. <i>Frontiers in Communication</i> , 2020, 5, .	1.3	38
341	Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer. <i>Cells</i> , 2020, 9, 1073.	4.3	38
342	Long non-coding RNAs in renal cell carcinoma: A systematic review and clinical implications. <i>Oncotarget</i> , 2017, 8, 48424-48435.	1.8	38

#	ARTICLE	IF	CITATIONS
343	Impact of biosurfactant and iron nanoparticles on biodegradation of polyaromatic hydrocarbons (PAHs). <i>Environmental Pollution</i> , 2022, 306, 119384.	7.7	38
344	Allelic imbalance in the clonal evolution of prostate carcinoma. <i>Cancer</i> , 1999, 85, 2017-2022.	4.1	37
345	Polysomy of Chromosomes 1 and/or 19 Is Common and Associated With Less Favorable Clinical Outcome in Oligodendrogliomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 618-624.	1.8	37
346	Novel markers of squamous differentiation in the urinary bladder. <i>Human Pathology</i> , 2013, 44, 1989-1997.	2.4	37
347	Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 939-947.	3.0	37
348	Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 517-524.	3.2	37
349	Predictors of cancer progression in T1a prostate adenocarcinoma. <i>Cancer</i> , 1999, 85, 1300-1304.	4.1	36
350	Implications of cancer stem cells in the treatment of cancer. <i>Future Oncology</i> , 2006, 2, 723-731.	2.4	36
351	Phase I/II Trial of High Intensity Focused Ultrasound for the Treatment of Previously Untreated Localized Prostate Cancer. <i>Journal of Urology</i> , 2007, 178, 2366-2371.	3.9	36
352	Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate. <i>Modern Pathology</i> , 2007, 20, 175-182.	5.8	36
353	Evidence for Transformation of Fibroadenoma of the Breast to Malignant Phyllodes Tumor. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2009, 17, 345-350.	1.3	36
354	Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine. <i>Cancers</i> , 2019, 11, 1152.	3.9	36
355	Towards a new WHO classification of renal cell tumor: what the clinician needs to know—a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 1506-1520.	1.4	36
356	Allelic Loss of the Active X Chromosome During Bladder Carcinogenesis. <i>Archives of Pathology and Laboratory Medicine</i> , 2004, 128, 187-190.	2.6	36
357	Invasion of fat justifies assignment of stage pT3a in prostatic adenocarcinoma. <i>Pathology</i> , 2006, 38, 309-311.	0.7	35
358	PAX8 expression in sporadic hemangioblastoma of the kidney supports a primary renal cell lineage: implications for differential diagnosis. <i>Human Pathology</i> , 2013, 44, 2247-2255.	2.4	35
359	Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR. <i>Human Pathology</i> , 2015, 46, 805-812.	2.4	35
360	TERT Promoter Mutations Occur Frequently in Urothelial Papilloma and Papillary Urothelial Neoplasm of Low Malignant Potential. <i>European Urology</i> , 2017, 71, 497-498.	5.1	35

#	ARTICLE	IF	CITATIONS
361	Fluorescence <i>in situ</i> hybridization in surgical pathology: principles and applications. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 73-99.	2.9	35
362	Well-Differentiated Thyroid Cancer Neovasculature Expresses Prostate-Specific Membrane Antigen—a Possible Novel Therapeutic Target. <i>Endocrine Pathology</i> , 2017, 28, 339-344.	10.4	35
363	Multiple Attacks Detection in Cyber-Physical Systems Using Random Finite Set Theory. <i>IEEE Transactions on Cybernetics</i> , 2020, 50, 4066-4075.	10.1	35
364	Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors. <i>Human Pathology</i> , 2008, 39, 1205-1211.	2.4	34
365	Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 843-864.	2.5	34
366	Unique clinicopathologic and molecular characteristics of urinary bladder tumors in children and young adults. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 414-426.	1.8	34
367	Ovarian Tissue Cryopreservation in Young Females Through the Oncofertility Consortium’s National Physicians Cooperative. <i>Future Oncology</i> , 2018, 14, 363-378.	2.4	34
368	Caffeine Improves Triathlon Performance: A Field Study in Males and Females. <i>International Journal of Sport Nutrition and Exercise Metabolism</i> , 2018, 28, 228-237.	2.1	34
369	EWSR1-PATZ1 fusion renal cell carcinoma: a recurrent gene fusion characterizing thyroid-like follicular renal cell carcinoma. <i>Modern Pathology</i> , 2021, 34, 1921-1934.	5.8	34
370	More than money: establishing the importance of a sense of purpose for salespeople. <i>Journal of the Academy of Marketing Science</i> , 2022, 50, 272-295.	11.6	34
371	Hypermethylation of tumor-suppressor gene CpG islands in small-cell carcinoma of the urinary bladder. <i>Modern Pathology</i> , 2008, 21, 355-362.	5.8	33
372	Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer?. <i>BJU International</i> , 2009, 103, 1058-1063.	2.8	33
373	Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer. <i>Human Pathology</i> , 2018, 71, 20-29.	2.4	33
374	Non-urothelial carcinomas of the bladder. <i>Histopathology</i> , 2019, 74, 97-111.	3.1	33
375	Functional alterations caused by mutations reflect evolutionary trends of SARS-CoV-2. <i>Briefings in Bioinformatics</i> , 2021, 22, 1442-1450.	6.6	33
376	Mutation and expression analysis of the p73 gene in prostate cancer. <i>Prostate</i> , 1999, 39, 94-100.	2.3	32
377	Mixed Epithelial and Stromal Tumors of the Kidney. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1114-1122.	4.0	32
378	Renal cell carcinoma with smooth muscle stroma lacks chromosome 3p and VHL alterations. <i>Modern Pathology</i> , 2014, 27, 765-774.	5.8	32



#	ARTICLE	IF	CITATIONS
379	The origin of prostate metastases: emerging insights. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 765-773.	6.3	32
380	Tubulocystic renal cell carcinoma is an entity that is immunohistochemically and genetically distinct from papillary renal cell carcinoma. <i>Histopathology</i> , 2016, 68, 850-857.	3.1	32
381	Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 175-181.	3.9	32
382	Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon. <i>Human Pathology</i> , 2017, 65, 133-139.	2.4	32
383	Autoimmune disease variants regulate <i>GSDMB</i> gene expression in human immune cells and whole blood. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E7860-E7862.	7.6	32
384	NADPH oxidase 5 (NOX5)-induced reactive oxygen signaling modulates normoxic HIF1 $\alpha$ and p27 <sup>Kip1</sup> expression in malignant melanoma and other human tumors. <i>Molecular Carcinogenesis</i> , 2017, 56, 2643-2662.	2.9	32
385	Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. <i>Cancers</i> , 2019, 11, 830.	3.9	32
386	RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. <i>Journal of Clinical Pathology</i> , 2019, 72, 135-139.	2.2	32
387	Low-grade oncocytic tumour expands the spectrum of renal oncocytic tumours and deserves separate classification: a review of 23 cases from a single tertiary institute. <i>Journal of Clinical Pathology</i> , 2022, 75, 772-775.	2.2	32
388	MicroRNA and Transcription Factor Mediated Regulatory Network Analysis Reveals Critical Regulators and Regulatory Modules in Myocardial Infarction. <i>PLoS ONE</i> , 2015, 10, e0135339.	2.4	32
389	Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice. <i>Current Drug Metabolism</i> , 2017, 18, 712-722.	1.3	32
390	CHARACTERIZATION AND PREDICTORS OF PROSTATE SPECIFIC ANTIGEN PROGRESSION RATES AFTER RADICAL RETROPUBIC PROSTATECTOMY. <i>Journal of Urology</i> , 2000, 164, 749-753.	3.9	31
391	Validation of 34betaE12 immunoexpression in clear cell papillary renal cell carcinoma as a sensitive biomarker. <i>Pathology</i> , 2017, 49, 10-18.	0.7	31
392	Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. <i>European Urology Focus</i> , 2017, 3, 590-598.	3.4	31
393	Energy efficient COD and N-removal from high-strength wastewater by a passively aerated GAO dominated biofilm. <i>Bioresource Technology</i> , 2019, 283, 148-158.	9.7	31
394	Detecting and phenotyping of aneuploid circulating tumor cells in patients with various malignancies. <i>Cancer Biology and Therapy</i> , 2019, 20, 546-551.	3.7	31
395	Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization. <i>Human Pathology</i> , 2009, 40, 211-217.	2.4	30
396	Extranodal extension of lymph node metastasis is a marker of poor prognosis in oesophageal cancer: a systematic review with meta-analysis. <i>Journal of Clinical Pathology</i> , 2016, 69, 956-961.	2.2	30

#	ARTICLE	IF	CITATIONS
397	The utility of CDX2, GATA3, and DOG1 in the diagnosis of testicular neoplasms: an immunohistochemical study of 109 cases. <i>Human Pathology</i> , 2016, 48, 18-24.	2.4	30
398	Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2017, 7, 2374.	3.5	30
399	The potent small molecule integrin antagonist THR-687 is a promising next-generation therapy for retinal vascular disorders. <i>Experimental Eye Research</i> , 2019, 180, 43-52.	2.7	30
400	Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded. <i>Pathology</i> , 2020, 52, 192-196.	0.7	30
401	SCovid: single-cell atlases for exposing molecular characteristics of COVID-19 across 10 human tissues. <i>Nucleic Acids Research</i> , 2022, 50, D867-D874.	14.2	30
402	Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: A fluorescence in situ hybridization and immunohistochemical analysis. <i>Prostate</i> , 2008, 68, 919-923.	2.3	29
403	Cystic partially regressed clear cell renal cell carcinoma: a potential mimic of multilocular cystic renal cell carcinoma. <i>Histopathology</i> , 2013, 63, 767-779.	3.1	29
404	The Application of Immunohistochemical Biomarkers in Urologic Surgical Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 1643-1665.	2.6	29
405	Benign perivascular myoid cell tumor (myopericytoma) of the urinary tract: a report of 2 cases with an emphasis on differential diagnosis. <i>Human Pathology</i> , 2014, 45, 1115-1121.	2.4	29
406	Increased androgen receptor gene copy number is associated with <i>TMPRSS2-ERG</i> rearrangement in prostatic small cell carcinoma. <i>Molecular Carcinogenesis</i> , 2015, 54, 900-907.	2.9	29
407	Tp53 and its potential therapeutic role as a target in bladder cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 401-414.	3.4	29
408	Rs4878104 contributes to Alzheimer's disease risk and regulates DAPK1 gene expression. <i>Neurological Sciences</i> , 2017, 38, 1255-1262.	2.0	29
409	Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities. <i>Molecular Oncology</i> , 2019, 13, 2259-2277.	4.8	29
410	Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients. <i>Human Pathology</i> , 2019, 90, 27-36.	2.4	29
411	The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5683.	4.2	29
412	Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 231-243.	3.4	29
413	Polymorphonuclear MDSCs are enriched in the stroma and expanded in metastases of prostate cancer. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 171-177.	2.9	29
414	Is it necessary to separate clinical stage T1c from T2 prostate adenocarcinoma?. <i>BJU International</i> , 2005, 96, 777-780.	2.8	28



#	ARTICLE	IF	CITATIONS
415	Small-cell carcinoma of the urinary bladder: diagnosis and management. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1707-1713.	2.5	28
416	Molecular Genetic Evidence of an Independent Origin of Serous Low Malignant Potential Implants and Lymph Node Inclusions. <i>International Journal of Gynecological Pathology</i> , 2007, 26, 387-394.	1.6	28
417	Critical Evaluation of the Prostate from Cystoprostatectomies for Bladder Cancer: Insights from a Complete Sampling with the Whole Mount Technique. <i>European Urology</i> , 2009, 55, 1305-1309.	5.1	28
418	Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy. <i>Molecular Cancer</i> , 2014, 13, 39.	20.3	28
419	Modeling hepatitis B virus infection, immunopathology and therapy in mice. <i>Antiviral Research</i> , 2015, 121, 1-8.	4.2	28
420	Renal cell carcinoma with TFE3 translocation and succinate dehydrogenase B mutation. <i>Modern Pathology</i> , 2017, 30, 407-415.	5.8	28
421	Endocannabinoid-Dependent Long-Term Potentiation of Synaptic Transmission at Rat Barrel Cortex. <i>Cerebral Cortex</i> , 2018, 28, 1568-1581.	3.2	28
422	Identification of Cancer Dysfunctional Subpathways by Integrating DNA Methylation, Copy Number Variation, and Gene-Expression Data. <i>Frontiers in Genetics</i> , 2019, 10, 441.	2.4	28
423	Clear cell renal cell carcinoma with wild-type von Hippel-Lindau gene: a non-existent or new tumour entity?. <i>Histopathology</i> , 2019, 74, 60-67.	3.1	28
424	Clinicopathologic analysis of upper urinary tract carcinoma with variant histology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 111-120.	3.0	28
425	The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. <i>Advances in Anatomic Pathology</i> , 2021, 28, 179-195.	4.4	28
426	Molecular pathology of urothelial carcinoma. <i>Human Pathology</i> , 2021, 113, 67-83.	2.4	28
427	Oncotargets in Different Renal Cancer Subtypes. <i>Current Drug Targets</i> , 2015, 16, 125-135.	2.3	28
428	Conserved Genetic Findings in Metastatic Bladder Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2001, 125, 1197-1199.	2.6	28
429	Large cell undifferentiated carcinoma of the urinary bladder. <i>Pathology</i> , 2010, 42, 364-368.	0.7	27
430	T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-II $\pm$ , survivin, and E-cadherin. <i>Human Pathology</i> , 2016, 57, 78-84.	2.4	27
431	Eosinophilic Otitis Media: the Aftermath of Eosinophil Extracellular Trap Cell Death. <i>Current Allergy and Asthma Reports</i> , 2017, 17, 33.	5.2	27
432	Iatrogenic changes in the urinary tract. <i>Histopathology</i> , 2017, 70, 10-25.	3.1	27

#	ARTICLE	IF	CITATIONS
433	Continuous biological sulfate reduction from phosphogypsum waste leachate. <i>Hydrometallurgy</i> , 2018, 180, 1-6.	4.5	27
434	Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. <i>Cancer Treatment Reviews</i> , 2018, 68, 80-85.	8.1	27
435	Digital pathology and COVID-19 and future crises: pathologists can safely diagnose cases from home using a consumer monitor and a mini PC. <i>Journal of Clinical Pathology</i> , 2020, 73, 695-696.	2.2	27
436	SubtypeDrug: a software package for prioritization of candidate cancer subtype-specific drugs. <i>Bioinformatics</i> , 2021, 37, 2491-2493.	4.2	27
437	Neoplasms of the urinary bladder. , 2008, , 258-351.		27
438	Molecular Foundations for Personalized Therapy in Prostate Cancer. <i>Current Drug Targets</i> , 2015, 16, 103-114.	2.3	27
439	CWR22 Xenograft as an Ex Vivo Human Tumor Model for Prostate Cancer Gene Therapy. <i>Journal of the National Cancer Institute</i> , 1996, 88, 607-611.	6.6	26
440	Predicting extravesical extension of bladder carcinoma: a novel method based on micrometer measurement of the depth of invasion in transurethral resection specimens. <i>Urology</i> , 2000, 55, 668-672.	1.4	26
441	Interphase cytogenetic analysis with centromeric probes for chromosomes 1, 2, 6, 10, and 17 in 11 tumors from a patient with bilateral renal oncocytosis. <i>Modern Pathology</i> , 2008, 21, 498-504.	5.8	26
442	Atypical sclerosing adenosis of the prostate: a rare mimic of adenocarcinoma. <i>Histopathology</i> , 2010, 56, 627-631.	3.1	26
443	Do Not Misinterpret Intraductal Carcinoma of the Prostate as High-grade Prostatic Intraepithelial Neoplasia!. <i>European Urology</i> , 2012, 62, 518-522.	5.1	26
444	Immunoglobulin G4-related Disease in Genitourinary Organs: An Emerging Fibroinflammatory Entity Often Misdiagnosed Preoperatively as Cancer. <i>European Urology</i> , 2013, 64, 865-872.	5.1	26
445	Integration of Multiple Genomic and Phenotype Data to Infer Novel miRNA-Disease Associations. <i>PLoS ONE</i> , 2016, 11, e0148521.	2.4	26
446	Prostate cancer: from Gleason scoring to prognostic grade grouping. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 433-440.	2.5	26
447	Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma. <i>European Urology Focus</i> , 2018, 4, 880-888.	3.4	26
448	Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. <i>Clinical Drug Investigation</i> , 2019, 39, 503-519.	2.3	26
449	Î±-Methylacyl Coenzyme A Racemase, Ki-67, and Topoisomerase Î² in Cystoprostatectomies With Incidental Prostate Cancer. <i>American Journal of Clinical Pathology</i> , 2007, 128, 657-664.	0.8	25
450	Positive-block Ratio in Radical Prostatectomy Specimens is an Independent Predictor of Prostate-specific Antigen Recurrence. <i>American Journal of Surgical Pathology</i> , 2007, 31, 877-881.	4.0	25

#	ARTICLE	IF	CITATIONS
451	Lymphoepithelioma-like carcinoma of the prostate. <i>Human Pathology</i> , 2009, 40, 982-987.	2.4	25
452	Current treatment of metastatic bladder cancer and future directions. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1851-1862.	2.5	25
453	Is atypical adenomatous hyperplasia of the prostate a precursor lesion?. <i>Prostate</i> , 2011, 71, 1746-1751.	2.3	25
454	Molecular genetic evidence supporting the neoplastic nature of fibrous stroma in testicular teratoma. <i>Modern Pathology</i> , 2012, 25, 1432-1438.	5.8	25
455	Cholesterol Sulfonation Enzyme, SULT2B1b, Modulates AR and Cell Growth Properties in Prostate Cancer. <i>Molecular Cancer Research</i> , 2016, 14, 776-786.	3.5	25
456	Exploring Small Extracellular Vesicles for Precision Medicine in Prostate Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 221.	3.0	25
457	MRTFB regulates the expression of NOMO1 in colon. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 7568-7569.	7.6	25
458	International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. <i>European Urology Focus</i> , 2022, 8, 438-446.	3.4	25
459	Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives. <i>Current Drug Metabolism</i> , 2017, 18, 700-711.	1.3	25
460	Molecular Evidence Supporting the Neoplastic Nature of Some Epidermoid Cysts of the Testis. <i>Archives of Pathology and Laboratory Medicine</i> , 2003, 127, 858-860.	2.6	25
461	Does the Presence of Extranodal Extension in Pathological Stage B1 Nonseminomatous Germ Cell Tumor Necessitate Adjuvant Chemotherapy?. <i>Journal of Urology</i> , 2007, 177, 944-946.	3.9	24
462	Solitary Fibrous Tumour of the Prostate Identified on Needle Biopsy. <i>European Urology</i> , 2009, 56, 564-567.	5.1	24
463	Joint Appraisal of the Radical Prostatectomy Specimen by the Urologist and the Uropathologist: Together, We Can Do It Better. <i>European Urology</i> , 2009, 56, 951-955.	5.1	24
464	The clinical and therapeutic implications of cancer stem cell biology. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1133-1145.	2.5	24
465	<i>KRAS</i> mutation is present in a small subset of primary urinary bladder adenocarcinomas. <i>Histopathology</i> , 2012, 61, 1036-1042.	3.1	24
466	Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1367-1369.	2.5	24
467	Perspectives on testicular sex cord-stromal tumors and those composed of both germ cells and sex cord-stromal derivatives with a comparison to corresponding ovarian neoplasms. <i>Human Pathology</i> , 2017, 65, 1-14.	2.4	24
468	Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 685-693.	2.5	24

#	ARTICLE	IF	CITATIONS
469	Systematic identification and analysis of dysregulated miRNA and transcription factor feedforward loops in hypertrophic cardiomyopathy. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 306-316.	3.6	24
470	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2020, 12, 84.	3.9	24
471	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. <i>Advances in Anatomic Pathology</i> , 2021, 28, 196-208.	4.4	24
472	A Review of Recent Advances and Research on Drug Target Identification Methods. <i>Current Drug Metabolism</i> , 2019, 20, 209-216.	1.3	24
473	TREATMENT CHANGES IN PROSTATIC HYPERPLASIA AND CANCER, INCLUDING ANDROGEN DEPRIVATION THERAPY AND RADIOTHERAPY. <i>Urologic Clinics of North America</i> , 1999, 26, 465-479.	2.0	23
474	IMPACT OF THE NUMBER OF POSITIVE LYMPH NODES ON DISEASE-FREE SURVIVAL IN PATIENTS WITH PATHOLOGICAL STAGE B1 NONSEMINOMATOUS GERM CELL TUMOR. <i>Journal of Urology</i> , 2005, 174, 143-145.	3.9	23
475	Retroperitoneal Seminoma in Limited Biopsies: Morphologic Criteria and Immunohistochemical Findings in 30 Cases. <i>American Journal of Surgical Pathology</i> , 2006, 30, 766-773.	4.0	23
476	Lymphatic vessel density in radical prostatectomy specimens. <i>Human Pathology</i> , 2008, 39, 610-615.	2.4	23
477	Epidermal growth factor receptor protein expression and gene amplification in the chemorefractory metastatic embryonal carcinoma. <i>Modern Pathology</i> , 2009, 22, 7-12.	5.8	23
478	Inverted (Endophytic) Noninvasive Lesions and Neoplasms of the Urothelium: The Cinderella Group Has Yet to Be Fully Exploited. <i>European Urology</i> , 2011, 59, 225-230.	5.1	23
479	Central Prostate Pathology Review: Should It Be Mandatory?. <i>European Urology</i> , 2013, 64, 199-201.	5.1	23
480	Open vs. robotic-assisted radical prostatectomy: A single surgeon and pathologist comparison of pathologic and oncologic outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1043-1048.	1.8	23
481	FGFR3 and Cyclin D3 as Urine Biomarkers of Bladder Cancer Recurrence. <i>Biomarkers in Medicine</i> , 2016, 10, 243-253.	1.4	23
482	TERT Promoter Mutation Status in Sarcomatoid Urothelial Carcinomas of the Upper Urinary Tract. <i>Future Oncology</i> , 2017, 13, 705-714.	2.4	23
483	Solitary fibrous tumour of the genitourinary tract: a clinicopathological study of 11 cases and their association with the NAB2-STAT6 fusion gene. <i>Journal of Clinical Pathology</i> , 2017, 70, 508-514.	2.2	23
484	Lymphoepithelioma-like carcinoma of the upper urinary tract. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 703-709.	3.0	23
485	Next-Generation Sequencing to Detect Deletion of RB1 and ERBB4 Genes in Chromophobe Renal Cell Carcinoma. <i>American Journal of Pathology</i> , 2018, 188, 846-852.	4.2	23
486	Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy. <i>Cancers</i> , 2019, 11, 196.	3.9	23

#	ARTICLE	IF	CITATIONS
487	Peptide-Major Histocompatibility Complex Class I Binding Prediction Based on Deep Learning With Novel Feature. <i>Frontiers in Genetics</i> , 2019, 10, 1191.	2.4	23
488	The applicability and utility of immunohistochemical biomarkers in bladder pathology. <i>Human Pathology</i> , 2020, 98, 32-55.	2.4	23
489	Low-grade oncocytic tumour of the kidney is characterised by genetic alterations of <i>TSC1</i> , <i>TSC2</i> , <i>MTOR</i> or <i>PIK3CA</i> and consistent <i>GATA3</i> positivity. <i>Histopathology</i> , 2023, 82, 296-304.	3.1	23
490	Loss of Heterozygosity Analysis Identifies Genetic Abnormalities in <i>Mycosis Fungoides</i> and Specific Loci Associated With Disease Progression. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1552-1556.	4.0	22
491	Pathology of the prostate in radical cystectomy specimens: A critical review. <i>Surgical Oncology</i> , 2009, 18, 73-84.	1.9	22
492	Pathological characterization of unifocal prostate cancers in whole-mount radical prostatectomy specimens. <i>BJU International</i> , 2011, 107, 1587-1591.	2.8	22
493	Elevated expression of cancer-associated proliferating cell nuclear antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer. <i>Prostate</i> , 2011, 71, 748-754.	2.3	22
494	Human Papillomavirus is Not an Etiologic Agent of Urothelial Inverted Papillomas. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1223-1228.	4.0	22
495	Lymph node metastases in patients with urothelial carcinoma variants: Influence of the specific variant on nodal histology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 20.e23-20.e29.	1.8	22
496	Photoacoustic tomography of intact human prostates and vascular texture analysis identify prostate cancer biopsy targets. <i>Photoacoustics</i> , 2018, 11, 46-55.	8.1	22
497	Challenges in Pathologic Staging of Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1253-1261.	4.0	22
498	Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation. <i>Oncotarget</i> , 2017, 8, 54096-54105.	1.8	22
499	Predicting Tumor Volume in Radical Prostatectomy Specimens From Patients With Prostate Cancer. <i>American Journal of Clinical Pathology</i> , 2003, 120, 386-391.	0.8	21
500	2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections. <i>European Urology Supplements</i> , 2009, 8, 453-457.	0.5	21
501	Telomere shortening distinguishes inverted urothelial neoplasms. <i>Histopathology</i> , 2013, 62, 595-601.	3.1	21
502	Atypical Adenomatous Hyperplasia of Prostate Lacks <i>TMPRSS2-ERG</i> Gene Fusion. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1550-1554.	4.0	21
503	Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder. <i>PLoS ONE</i> , 2015, 10, e0127908.	2.4	21
504	Emerging Immunotargets in Metastatic Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2016, 17, 771-776.	2.3	21

#	ARTICLE	IF	CITATIONS
505	Primary mucinous adenocarcinoma of the female urethra: a contemporary clinicopathologic analysis. <i>Human Pathology</i> , 2016, 47, 132-137.	2.4	21
506	Clear cell renal cell tumors: Not all that is "clear" is cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 292.e17-292.e22.	1.8	21
507	Eruptive and shallow conduit dynamics during Vulcanian explosions: insights from the Episode IV block field of the 1912 eruption of Novarupta, Alaska. <i>Bulletin of Volcanology</i> , 2017, 79, 1.	3.1	21
508	Distinction of intrahepatic metastasis from multicentric carcinogenesis in multifocal hepatocellular carcinoma using molecular alterations. <i>Human Pathology</i> , 2018, 72, 127-134.	2.4	21
509	Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 397.	3.0	21
510	Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 645-655.	3.4	21
511	The microRNA pathway is involved in <i>Spodoptera frugiperda</i> (Sf9) cells antiviral immune defense against <i>Autographa californica</i> multiple nucleopolyhedrovirus infection. <i>Insect Biochemistry and Molecular Biology</i> , 2019, 112, 103202.	2.7	21
512	A Positive Causal Influence of IL-18 Levels on the Risk of T2DM: A Mendelian Randomization Study. <i>Frontiers in Genetics</i> , 2019, 10, 295.	2.4	21
513	Microbiome and Cancers, With Focus on Genitourinary Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 178.	3.0	21
514	Gonadoblastoma: origin and outcome. <i>Human Pathology</i> , 2020, 100, 47-53.	2.4	21
515	Conjoint Feature Representation of GO and Protein Sequence for PPI Prediction Based on an Inception RNN Attention Network. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 22, 198-208.	5.2	21
516	Granular necrosis: a distinctive form of cell death in malignant tumours. <i>Pathology</i> , 2020, 52, 507-514.	0.7	21
517	Recurrent KRAS mutations are early events in the development of papillary renal neoplasm with reverse polarity. <i>Modern Pathology</i> , 2022, 35, 1279-1286.	5.8	21
518	World Health Organization and International Society of Urological Pathology classification and Two-number grading system of bladder tumors. <i>Cancer</i> , 2000, 88, 1513-1516.	4.1	20
519	Analysis of loss of heterozygosity and X chromosome inactivation in spleens with myeloproliferative disorders and acute myeloid leukemia. <i>Modern Pathology</i> , 2005, 18, 1562-1568.	5.8	20
520	Screening for Intratubular Germ Cell Neoplasia of the Testis Using OCT4 Immunohistochemistry. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1427-1431.	4.0	20
521	Clonal relationships between epidermotropic metastatic melanomas and their primary lesions: a loss of heterozygosity and X-chromosome inactivation-based analysis. <i>Modern Pathology</i> , 2007, 20, 821-827.	5.8	20
522	Anatomic, morphologic and genetic heterogeneity of prostate cancer: implications for clinical practice. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1371-1374.	2.5	20

#	ARTICLE	IF	CITATIONS
523	Urethral caruncle: a lesion related to IgG4-associated sclerosing disease?. Journal of Clinical Pathology, 2013, 66, 559-562.	2.2	20
524	Clear Cell Renal Cell Carcinoma (ccRCC) with Hemangioblastoma-like Features: A Previously Unreported Pattern of ccRCC with Possible Clinical Significance. European Urology, 2014, 66, 806-810.	5.1	20
525	Cytoplasmic OCT4 staining is a sensitive marker of neuroendocrine differentiation. Human Pathology, 2014, 45, 27-32.	2.4	20
526	Long Non-coding RNAs in Prostate Cancer with Emphasis on Second Chromosome Locus Associated with Prostate-1 Expression. Frontiers in Oncology, 2017, 7, 305.	3.0	20
527	Emerging Prognostic Biomarkers in Testicular Germ Cell Tumors: Looking Beyond Established Practice. Frontiers in Oncology, 2018, 8, 571.	3.0	20
528	Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer. Apmsis, 2019, 127, 545-553.	2.0	20
529	Iodide-assisted leaching of chalcopyrite in acidic ferric sulfate media. Hydrometallurgy, 2019, 186, 244-251.	4.5	20
530	Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges. Frontiers in Oncology, 2019, 9, 228.	3.0	20
531	Chronic sleep disturbance, not chronic sleep deprivation, is associated with self-rated health in adolescents. Preventive Medicine, 2019, 124, 11-16.	3.6	20
532	Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder. Journal of Clinical Pathology, 2021, 74, 491-495.	2.2	20
533	SubLocEP: a novel ensemble predictor of subcellular localization of eukaryotic mRNA based on machine learning. Briefings in Bioinformatics, 2021, 22, .	6.6	20
534	Process optimization, exergy and economic analysis of boil-off gas re-liquefaction processes for LNG carriers. Energy, 2022, 242, 122947.	9.0	20
535	Is prostate-specific antigen (PSA) density better than the preoperative PSA level in predicting early biochemical recurrence of prostate cancer after radical prostatectomy?. BJU International, 2006, 97, 480-484.	2.8	19
536	Tumor Focality Does Not Predict Biochemical Recurrence After Radical Prostatectomy in Men With Clinically Localized Prostate Cancer. Journal of Urology, 2011, 186, 506-510.	3.9	19
537	Molecular characteristics of urothelial neoplasms in children and young adults: a subset of tumors from young patients harbors chromosomal abnormalities but not FGFR3 or TP53 gene mutations. Modern Pathology, 2014, 27, 1540-1548.	5.8	19
538	Seminal Vesicle Intraepithelial Neoplasia Versus Basal Cell Hyperplasia in a Seminal Vesicle. European Urology, 2014, 66, 623-627.	5.1	19
539	Inflammatory myofibroblastic tumour of the urinary bladder: the role of immunoglobulin G4 and the comparison of two immunohistochemical antibodies and fluorescence in situ hybridization for the detection of anaplastic lymphoma kinase alterations. Histopathology, 2015, 67, 20-38.	3.1	19
540	New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. Cancer Treatment Reviews, 2015, 41, 614-622.	8.1	19



#	ARTICLE	IF	CITATIONS
541	The Cancer Genomics Resource List 2014. Archives of Pathology and Laboratory Medicine, 2015, 139, 989-1008.	2.6	19
542	Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. European Urology, 2016, 69, 186-190.	5.1	19
543	Thin films of fluorinated groups substituted metallophthalocyanines as an optical material. Inorganic Chemistry Communication, 2017, 86, 209-212.	4.0	19
544	Classical gonadoblastoma: its relationship to the "dissecting" variant and undifferentiated gonadal tissue. Histopathology, 2018, 72, 545-555.	3.1	19
545	pqsfinder web: G-quadruplex prediction using optimized pqsfinder algorithm. Bioinformatics, 2020, 36, 2584-2586.	4.2	19
546	A comprehensive review for gut microbes: technologies, interventions, metabolites and diseases. Briefings in Functional Genomics, 2021, 20, 42-60.	2.8	19
547	Immunohistochemical Characterization of 120 Testicular Sex Cord-Stromal Tumors With an Emphasis on the Diagnostic Utility of SOX9, FOXL2, and SF-1. American Journal of Surgical Pathology, 2021, 45, 1303-1313.	4.0	19
548	Prognostic and clinicopathological role of long non-coding RNA UCA1 in various carcinomas. Oncotarget, 2017, 8, 28373-28384.	1.8	19
549	Metabolic Alterations in Renal and Prostate Cancer. Current Drug Metabolism, 2016, 17, 150-155.	1.3	19
550	ELECTRA-DTA: a new compound-protein binding affinity prediction model based on the contextualized sequence encoding. Journal of Cheminformatics, 2022, 14, 14.	6.4	19
551	Coupling effect of biocementation-fiber reinforcement on mechanical behavior of calcareous sand for ocean engineering. Bulletin of Engineering Geology and the Environment, 2022, 81, 1.	3.5	19
552	Carcinomas of Ovary and Lung With Clear Cell Features. International Journal of Gynecological Pathology, 2007, 26, 134-140.	1.6	18
553	Prise en charge de la piÃ©ce de prostatectomie radicale. RÃ©sultats de la confÃ©rence de consensus de la SociÃ©tÃ© internationale d'urologie (ISUP). Annales De Pathologie, 2013, 33, 155-161.	0.2	18
554	Utilization of cell-transferred cytologic smears in detection of EGFR and KRAS mutation on adenocarcinoma of lung. Modern Pathology, 2014, 27, 930-935.	5.8	18
555	Widespread telomere instability in prostatic lesions. Molecular Carcinogenesis, 2016, 55, 842-852.	2.9	18
556	Chromosome 12p abnormalities and IMP3 expression in prepubertal pure testicular teratomas. Human Pathology, 2016, 49, 54-60.	2.4	18
557	Concomitant bladder cancer and prostate cancer: challenges and controversies. Nature Reviews Urology, 2017, 14, 620-629.	3.9	18
558	Immunotherapy in Renal Cell Carcinoma from Poverty to the Spoiled of Choice. Immunotherapy, 2019, 11, 1507-1521.	2.1	18



#	ARTICLE	IF	CITATIONS
559	Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma. <i>Modern Pathology</i> , 2019, 32, 330-337.	5.8	18
560	The Expression Patterns of p53 and p16 and an Analysis of a Possible Role of HPV in Primary Adenocarcinoma of the Urinary Bladder. <i>PLoS ONE</i> , 2014, 9, e95724.	2.4	18
561	Bladder Cancer: Molecular Determinants of Personalized Therapy. <i>Current Drug Targets</i> , 2015, 16, 115-124.	2.3	18
562	Molecular Classification of Bladder Urothelial Carcinoma Using NanoString-Based Gene Expression Analysis. <i>Cancers</i> , 2021, 13, 5500.	3.9	18
563	Down-regulation of fragile histidine triad expression in prostate carcinoma. <i>Cancer</i> , 2003, 97, 1447-1452.	4.1	17
564	Cyclin D3 gene amplification in bladder carcinoma in situ. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 457, 555-561.	3.0	17
565	Clonal origin of multifocal hepatocellular carcinoma. <i>Cancer</i> , 2010, 116, 4078-4085.	4.1	17
566	pT0 prostate cancer after radical prostatectomy. <i>Journal of Surgical Oncology</i> , 2010, 102, 331-333.	1.7	17
567	Premalignancy of the testis and paratestis. <i>Pathology</i> , 2013, 45, 264-272.	0.7	17
568	Annotating the Function of the Human Genome with Gene Ontology and Disease Ontology. <i>BioMed Research International</i> , 2016, 2016, 1-8.	2.0	17
569	Atypical Renal Cysts. <i>American Journal of Surgical Pathology</i> , 2016, 40, 202-211.	4.0	17
570	GT198 Expression Defines Mutant Tumor Stroma in Human Breast Cancer. <i>American Journal of Pathology</i> , 2016, 186, 1340-1350.	4.2	17
571	SMARCB1/INI1 Genetic Alterations in Renal Medullary Carcinomas. <i>European Urology</i> , 2016, 69, 1062-1064.	5.1	17
572	Prevalence and management of prostate cancer among East Asian men: Current trends and future perspectives. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 58.e1-58.e9.	1.8	17
573	Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients. <i>World Journal of Urology</i> , 2017, 35, 517-526.	2.4	17
574	Variants of Bladder Cancer: The Pathologist's Point of View. <i>European Urology Supplements</i> , 2017, 16, 210-222.	0.5	17
575	Complexity of the genomic landscape of renal cell carcinoma: Implications for targeted therapy and precision immuno-oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 119, 23-28.	4.6	17
576	DisSetSim: an online system for calculating similarity between disease sets. <i>Journal of Biomedical Semantics</i> , 2017, 8, 28.	1.6	17

#	ARTICLE	IF	CITATIONS
577	Mucinous intrahepatic cholangiocarcinoma: a distinct variant. <i>Human Pathology</i> , 2018, 78, 131-137.	2.4	17
578	“I wish someone had once asked me how I’m doing” Disadvantages and support needs faced by parents of long-term childhood cancer survivors. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27767.	1.6	17
579	Laparoscopic and Robotic-Assisted Partial Nephrectomy: An Overview of Hot Issues. <i>Urologia Internationalis</i> , 2020, 104, 669-677.	1.4	17
580	Gene fusion characterisation of rare aggressive prostate cancer variants—adenosquamous carcinoma, pleomorphic giant cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases. <i>Histopathology</i> , 2020, 77, 890-899.	3.1	17
581	Psychosocial determinants of women’s intentions and willingness to freeze their eggs. <i>Fertility and Sterility</i> , 2021, 115, 742-752.	1.0	17
582	An update on investigational therapies that target STAT3 for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 245-251.	4.2	17
583	Prostate Specific Membrane Antigen Targeted Positron Emission Tomography of Primary Prostate Cancer: Assessing Accuracy with Whole Mount Pathology. <i>Journal of Urology</i> , 2020, 203, 92-99.	3.9	17
584	T1 bladder carcinoma with variant histology: pathological features and clinical significance. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 989-998.	3.0	17
585	Pan-cancer analysis reveals sex-specific signatures in the tumor microenvironment. <i>Molecular Oncology</i> , 2022, 16, 2153-2173.	4.8	17
586	Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue. <i>Cancer Detection and Prevention</i> , 2002, 26, 238-244.	2.1	16
587	Stage pT0 in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and Patients: Why Is Cancer Not Present in the Radical Prostatectomy Specimen?. <i>European Urology</i> , 2009, 56, 272-274.	5.1	16
588	Renal cell carcinoma with clear cells, smooth muscle stroma, and negative for 3p deletion: a variant of renal angiomyoadenomatous tumour? A case report. <i>Histopathology</i> , 2013, 62, 522-524.	3.1	16
589	Cytoplasmic Staining of OCT4 Is a Highly Sensitive Marker of Adrenal Medullary-derived Tissue. <i>American Journal of Surgical Pathology</i> , 2013, 37, 727-733.	4.0	16
590	Influence of Histologic Criteria and Confounding Factors in Staging Equivocal Cases for Microscopic Perivesical Tissue Invasion (pT3a). <i>American Journal of Surgical Pathology</i> , 2014, 38, 167-175.	4.0	16
591	Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 303-309.	1.8	16
592	Genitourinary Small Cell Malignancies: Prostate and Bladder. <i>Future Oncology</i> , 2015, 11, 479-488.	2.4	16
593	Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence. <i>Cancer Biomarkers</i> , 2016, 17, 83-88.	1.7	16
594	Skin-Derived Precursors against UVB-Induced Apoptosis via Bcl-2 and Nrf2 Upregulation. <i>BioMed Research International</i> , 2016, 2016, 1-11.	2.0	16

#	ARTICLE	IF	CITATIONS
595	Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers. <i>Cancers</i> , 2019, 11, 1225.	3.9	16
596	Implementation of the 2018 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2/neu Assessment by FISH in breast cancers: predicted impact in a single institutional cohort. <i>Modern Pathology</i> , 2019, 32, 1566-1573.	5.8	16
597	Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain Reaction. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 722-725.	1.3	16
598	Mn(II) oxidation and manganese-oxide reduction on the decolorization of an azo dye. <i>International Biodeterioration and Biodegradation</i> , 2020, 146, 104820.	4.0	16
599	Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 262-268.	1.8	16
600	The Clinical Presentation of Culture-positive and Culture-negative, Quantitative Polymerase Chain Reaction (qPCR)-Attributable Shigellosis in the Global Enteric Multicenter Study and Derivation of a <i>Shigella</i> Severity Score: Implications for Pediatric <i>Shigella</i> Vaccine Trials. <i>Clinical Infectious Diseases</i> , 2021, 73, e569-e579.	5.7	16
601	Reallocating ventilators during the coronavirus disease 2019 pandemic: Is it ethical?. <i>Surgery</i> , 2020, 168, 388-391.	2.1	16
602	A high performance scalable fuzzy based modified Asymmetric Heterogeneous Multiprocessor System on Chip (Aht-MPSOC) reconfigurable architecture. <i>Journal of Intelligent and Fuzzy Systems</i> , 2022, 42, 647-658.	1.5	16
603	COVID-19 induces lower levels of IL-8, IL-10, and MCP-1 than other acute CRS-inducing diseases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.6	16
604	Expression of B7â€“H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas. <i>Human Pathology</i> , 2021, 113, 20-27.	2.4	16
605	Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey. <i>Journal of Clinical Pathology</i> , 2021, 74, 291-299.	2.2	16
606	The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges. <i>Human Pathology</i> , 2023, 136, 123-143.	2.4	16
607	Prostatic Intraepithelial Neoplasia: An Update. <i>Clinical Prostate Cancer</i> , 2004, 3, 26-30.	2.1	15
608	Molecular Genetic Evidence Supporting the Neoplastic Nature of the Leydig Cell Component of Ovarian Sertoli-Leydig Cell Tumors. <i>International Journal of Gynecological Pathology</i> , 2007, 26, 368-374.	1.6	15
609	Clonal evidence for the progression of a testicular germ cell tumor to angiosarcoma. <i>Human Pathology</i> , 2010, 41, 139-144.	2.4	15
610	Evidence for clonal fibroblast proliferation and autoimmune process in idiopathic retroperitoneal fibrosis. <i>Human Pathology</i> , 2012, 43, 1875-1880.	2.4	15
611	Immunohistochemical expression of prostate tumour overexpressed 1 (PTOV1) in atypical adenomatous hyperplasia (AAH) of the prostate. <i>Cellular Oncology (Dordrecht)</i> , 2013, 36, 37-42.	4.4	15
612	Re: Multilocular Cystic Renal Cell Carcinoma with Focus on Clinical and Pathobiological Aspects. <i>European Urology</i> , 2013, 63, 400-401.	5.1	15

#	ARTICLE	IF	CITATIONS
613	Incidental prostate cancer in Asian men: High prevalence of incidental prostatic adenocarcinoma in Chinese patients undergoing radical cystoprostatectomy for treatment of bladder cancer and selection of candidates for prostate-sparing cystectomy. <i>Prostate</i> , 2015, 75, 845-854.	2.3	15
614	Primary Cystic Trophoblastic Tumor of the Testis. <i>American Journal of Surgical Pathology</i> , 2017, 41, 788-794.	4.0	15
615	iatrogenic pathology of the urinary bladder. <i>Seminars in Diagnostic Pathology</i> , 2018, 35, 218-227.	2.3	15
616	Benign vascular tumors, cysts, and pseudocysts of the adrenal gland: a contemporary multi-institutional clinicopathological analysis of 55 cases. <i>Human Pathology</i> , 2018, 82, 95-102.	2.4	15
617	Distinct mutational landscape of inverted urothelial papilloma. <i>Journal of Pathology</i> , 2019, 249, 3-5.	4.5	15
618	Effects of familiarization on odor hedonic responses and food choices in children with autism spectrum disorders. <i>Autism</i> , 2019, 23, 1460-1471.	4.5	15
619	Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 449-458.	1.8	15
620	Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 755-763.	2.5	15
621	A Mendelian Randomization Study on Infant Length and Type 2 Diabetes Mellitus Risk. <i>Current Gene Therapy</i> , 2019, 19, 224-231.	2.1	15
622	Long-Term Follow-up of Untreated Stage T1a Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 1998, 90, 1105-1107.	6.6	14
623	Progression of T1 bladder tumors. <i>Cancer</i> , 1999, 86, 910-912.	4.1	14
624	DOES THE HISTOLOGY OF NODAL METASTASIS PREDICT SYSTEMIC RELAPSE AFTER RETROPERITONEAL LYMPH NODE DISSECTION IN PATHOLOGICAL STAGE B1 GERM CELL TUMORS?. <i>Journal of Urology</i> , 2005, 174, 1287-1290.	3.9	14
625	PATHOLOGICAL DEFINITION AND DIFFICULTIES IN ASSESSING POSITIVE MARGINS IN RADICAL PROSTATECTOMY SPECIMENS. <i>BJU International</i> , 2009, 103, 286-288.	2.8	14
626	Does the Size Matter?. <i>American Journal of Clinical Pathology</i> , 2010, 133, 662-668.	0.8	14
627	The route to personalized medicine in bladder cancer: where do we stand?. <i>Targeted Oncology</i> , 2015, 10, 325-336.	3.7	14
628	Evidence of a dual histogenetic pathway of sacrococcygeal teratomas. <i>Histopathology</i> , 2017, 70, 290-300.	3.1	14
629	Predictive Biomarkers for Immunotherapy in the Treatment of Advanced Urothelial Carcinoma: Where We Stand and Where We Go. <i>Future Oncology</i> , 2019, 15, 2199-2202.	2.4	14
630	MYB-NFIB gene fusion in prostatic basal cell carcinoma: clinicopathologic correlates and comparison with basal cell adenoma and florid basal cell hyperplasia. <i>Modern Pathology</i> , 2019, 32, 1666-1674.	5.8	14

#	ARTICLE	IF	CITATIONS
631	Functional brain networks in never-treated and treated long-term ill schizophrenia patients. <i>Neuropsychopharmacology</i> , 2019, 44, 1940-1947.	5.7	14
632	Identifying Alzheimer's disease-related proteins by LRRGD. <i>BMC Bioinformatics</i> , 2019, 20, 570.	2.7	14
633	Liquid biopsy in the clinical management of bladder cancer: current status and future developments. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 255-264.	3.4	14
634	Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 141-150.	3.4	14
635	Identification of a Multi-Long Noncoding RNA Signature for the Diagnosis of Type 1 Diabetes Mellitus. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 553.	4.2	14
636	Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives. <i>European Urology Focus</i> , 2021, 7, 955-963.	3.4	14
637	Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review. <i>European Urology Oncology</i> , 2021, 4, 558-569.	6.2	14
638	Microbial Surfactants are Next-Generation Biomolecules for Sustainable Remediation of Polyaromatic Hydrocarbons. , 2021, , 139-158.		14
639	Evaluating mismatch repair deficiency for solid tumor immunotherapy eligibility: immunohistochemistry versus microsatellite molecular testing. <i>Human Pathology</i> , 2021, 115, 10-18.	2.4	14
640	Bio-Cementation for Improving Soil Thermal Conductivity. <i>Sustainability</i> , 2021, 13, 10238.	3.3	14
641	Papillary urothelial neoplasms of low malignant potential. <i>Cancer</i> , 1999, 86, 2102-2108.	4.1	14
642	Epigenetic Modifications and Modulators in Prostate Cancer. <i>Critical Reviews in Oncogenesis</i> , 2017, 22, 439-450.	0.4	14
643	Estrogen deficiency is associated with hippocampal morphological remodeling of early postmenopausal mice. <i>Oncotarget</i> , 2017, 8, 21892-21902.	1.8	14
644	Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 1261-1268.	3.0	14
645	Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management. <i>Human Pathology</i> , 2023, 133, 56-75.	2.4	14
646	Visual estimation of tumour extent is not an independent predictor of prostate specific antigen recurrence. <i>BJU International</i> , 2005, 96, 1253-1257.	2.8	13
647	Proteomic-based approach for biomarkers discovery in early detection of invasive urothelial carcinoma. <i>Proteomics - Clinical Applications</i> , 2008, 2, 78-89.	1.9	13
648	Lymph node-positive bladder cancer: surgical, pathologic, molecular and prognostic aspects. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1281-1295.	2.5	13

#	ARTICLE	IF	CITATIONS
649	Renal cell carcinoma with rhabdoid features and loss of INI1 expression in an individual without sickle cell trait. <i>Pathology</i> , 2014, 46, 653-655.	0.7	13
650	Differential expression of $IMP3$ between male and female mature teratomas—immunohistochemical evidence of malignant nature. <i>Histopathology</i> , 2014, 65, 483-489.	3.1	13
651	EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder. <i>Modern Pathology</i> , 2014, 27, 107-112.	5.8	13
652	Unlike in clear cell renal cell carcinoma, KRAS is not mutated in multilocular cystic clear cell renal cell neoplasm of low potential. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 687-693.	3.0	13
653	Do clear cell papillary renal cell carcinomas occur in patients with von Hippel—Lindau disease?. <i>Human Pathology</i> , 2015, 46, 340-341.	2.4	13
654	Detection of BRAF Mutations on Direct Smears of Thyroid Fine-Needle Aspirates Through Cell Transfer Technique. <i>American Journal of Clinical Pathology</i> , 2015, 143, 500-504.	0.8	13
655	Whole Slide Imaging of Large Format Histology in Prostate Pathology: Potential for Information Fusion. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1460-1461.	2.6	13
656	The history of urologic pathology: an overview. <i>Histopathology</i> , 2019, 74, 184-212.	3.1	13
657	Insulinoma-associated Protein 1 (INSM1) Expression in Small Cell Neuroendocrine Carcinoma of the Urinary Tract. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 687-693.	1.3	13
658	Morphologic and Immunohistochemical Characteristics of Fluorescent In Situ Hybridization Confirmed TFE3-Gene Fusion Associated Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1450-1458.	4.0	13
659	Germline and Somatic Mutations in Prostate Cancer: Focus on Defective DNA Repair, PARP Inhibitors and Immunotherapy. <i>Future Oncology</i> , 2020, 16, 75-80.	2.4	13
660	Stage T1 bladder cancer: diagnostic criteria and pitfalls. <i>Pathology</i> , 2021, 53, 67-85.	0.7	13
661	Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5522.	4.2	13
662	Genomic characterization of hepatoid tumors: context matters. <i>Human Pathology</i> , 2021, 118, 30-41.	2.4	13
663	An Overview of Emerging Immunotargets of Genitourinary Tumors. <i>Current Drug Targets</i> , 2016, 17, 750-756.	2.3	13
664	PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay. <i>Current Drug Targets</i> , 2020, 21, 1664-1671.	2.3	13
665	The Assessment of Interleukin-18 on the Risk of Coronary Heart Disease. <i>Medicinal Chemistry</i> , 2020, 16, 626-634.	1.6	13
666	Targeting Protein Arginine Methyltransferase 5 Suppresses Radiation-induced Neuroendocrine Differentiation and Sensitizes Prostate Cancer Cells to Radiation. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 448-459.	3.7	13

#	ARTICLE	IF	CITATIONS
667	Classical pathology versus molecular pathology in renal cell carcinoma. <i>Current Urology Reports</i> , 2007, 8, 5-11.	2.3	12
668	Towards Personalized Therapy for Patients with Malignant Melanoma: Molecular Insights into the Biology of <i>BRAF</i> Mutations. <i>Future Oncology</i> , 2013, 9, 245-253.	2.4	12
669	Genetic mutations in accordance with a low malignant potential tumour are not demonstrated in clear cell papillary renal cell carcinoma. <i>Journal of Clinical Pathology</i> , 2016, 69, 547-550.	2.2	12
670	Neoplasms of the Kidney. , 2016, , 1645-1679.		12
671	Primary Choriocarcinoma of the Bladder: A Case Report and Review of Literature. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 188-191.	1.9	12
672	Mucin 5B, carbonic anhydrase 9 and claudin 18 are potential theranostic markers of gallbladder carcinoma. <i>Histopathology</i> , 2019, 74, 597-607.	3.1	12
673	Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma. <i>Pancreas</i> , 2019, 48, 70-76.	1.1	12
674	Walking with rhythmic auditory stimulation in chronic patients after stroke: A pilot randomized controlled trial. <i>Physiotherapy Research International</i> , 2020, 25, e1800.	1.5	12
675	Liquid biopsy in germ cell tumors: biology and clinical management. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 187-194.	3.4	12
676	Primary Renal Synovial Sarcomas: PAX 8 Immunostaining and Unusual Molecular Findings. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 221-228.	1.3	12
677	Narrative review: update on immunotherapy and pathological features in patients with bladder cancer. <i>Translational Andrology and Urology</i> , 2021, 10, 1521-1529.	1.4	12
678	Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy. <i>Current Drug Metabolism</i> , 2019, 20, 305-312.	1.3	12
679	Incorporating Transcriptomic-Metabolomic analysis reveal the effect of ultrasound on ethanol production in <i>Saccharomyces Cerevisiae</i> . <i>Ultrasonics Sonochemistry</i> , 2021, 79, 105791.	8.3	12
680	Relative promoter strengths in four human prostate cancer cell lines evaluated by particle bombardment-mediated gene transfer. <i>Prostate</i> , 2002, 51, 286-292.	2.3	11
681	Lymph node-positive prostate cancer: current issues, emerging technology and impact on clinical outcome. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1457-1469.	2.5	11
682	Pleomorphic xanthoastrocytoma and oligodendroglioma: collision of 2 morphologically and genetically distinct anaplastic components. <i>Journal of Neurosurgery</i> , 2011, 114, 1648-1653.	1.8	11
683	Does prostate acinar adenocarcinoma with Gleason Score 3 + 3 = 6 have the potential to metastasize?. <i>Diagnostic Pathology</i> , 2014, 9, 190.	2.1	11
684	The changing reality of urothelial bladder cancer: should non-squamous variant histology be managed as a distinct clinical entity?. <i>BJU International</i> , 2015, 116, 236-240.	2.8	11



#	ARTICLE	IF	CITATIONS
685	Testing PD-1/PD-L1 Expression in Cancer Therapy: Pathologic Insights and Economic Sustainability. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 501-502.	2.6	11
686	Neoadjuvant Chemotherapy in Urothelial Bladder Cancer: Impact of Regimen and Variant Histology. <i>Future Oncology</i> , 2016, 12, 1795-1804.	2.4	11
687	A contemporary series of renal masses with emphasis on recently recognized entities and tumors of low malignant potential: A report based on 624 consecutive tumors from a single tertiary center. <i>Pathology Research and Practice</i> , 2017, 213, 804-808.	2.3	11
688	Prostate cancer grading in 2018: limitations, implementations, cribriform morphology, and biological markers. <i>International Journal of Biological Markers</i> , 2018, 33, 331-334.	1.9	11
689	The molecular characterization and therapeutic strategies of papillary renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 169-175.	2.5	11
690	Molecular imaging and advanced MRI findings following immunotherapy in patients with brain tumors. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 9-15.	2.5	11
691	Reappraisal of the papillary urothelial neoplasm of low malignant potential (PUNLMP). <i>Histopathology</i> , 2020, 77, 525-535.	3.1	11
692	Immunotherapy for urothelial cancer: from the diagnostic pathologist's point of view. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 539-544.	3.2	11
693	Molecular characteristics of testicular germ cell tumors: pathogenesis and mechanisms of therapy resistance. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 75-79.	2.5	11
694	Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?. <i>Translational Andrology and Urology</i> , 2021, 10, 1530-1540.	1.4	11
695	Non-coding RNAs as Novel Biomarkers in Cancer Drug Resistance. <i>Current Medicinal Chemistry</i> , 2022, 29, 837-848.	2.5	11
696	Morphologic and Molecular Backgrounds for Personalized Management of Genito-Urinary Cancers: An Overview. <i>Current Drug Targets</i> , 2015, 16, 96-102.	2.3	11
697	Decision support systems for morphology-based diagnosis and prognosis of prostate neoplasms. <i>Cancer</i> , 2009, 115, 3068-3077.	4.1	10
698	Genetic profiles in renal tumors. <i>International Journal of Urology</i> , 2010, 17, 6-19.	1.3	10
699	Signet Ring Cell Carcinoma of the Testis. <i>American Journal of Surgical Pathology</i> , 2012, 36, 311-315.	4.0	10
700	Performance Evaluation Comparison of 3 Commercially Available PCR-based KRAS Mutation Testing Platforms. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2014, 22, 231-235.	1.3	10
701	Total submission of lymphadenectomy tissues removed during radical prostatectomy for prostate cancer: possible clinical significance of large-format histology. <i>Human Pathology</i> , 2014, 45, 2059-2062.	2.4	10
702	Re: Epithelial-to-mesenchymal Transition in Renal Neoplasms. <i>European Urology</i> , 2015, 68, 736-737.	5.1	10

#	ARTICLE	IF	CITATIONS
703	Present and Future of Personalized Medicine in Adult Genitourinary Tumors. <i>Future Oncology</i> , 2015, 11, 1381-1388.	2.4	10
704	Cervical Carcinomas With Neuroendocrine Differentiation: A Report of 28 Cases With Immunohistochemical Analysis and Molecular Genetic Evidence of Common Clonal Origin With Coexisting Squamous and Adenocarcinomas. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 372-384.	1.6	10
705	Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1029-1037.	2.5	10
706	On the histogenesis of mixed germ cell-sex cord stromal tumour of the gonads. <i>Journal of Clinical Pathology</i> , 2017, 70, 222-227.	2.2	10
707	Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach. <i>European Urology Supplements</i> , 2017, 16, 309-315.	0.5	10
708	Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples. <i>Cancer Cytopathology</i> , 2018, 126, 992-1002.	2.6	10
709	Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 131, 1-6.	4.6	10
710	Physiological stretch induced proliferation of human urothelial cells via integrin $\beta 6$ -FAK signaling pathway. <i>Neurourology and Urodynamics</i> , 2018, 37, 2114-2120.	1.6	10
711	Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, S137-S137.	1.7	10
712	Molecular Testing for EGFR Mutations and ALK Rearrangements in the Cytological Specimens From the Patients With Non-Small Cell Lung Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 119-124.	1.3	10
713	Histopathologic challenges: The second OPINION issue. <i>European Journal of Surgical Oncology</i> , 2019, 45, 12-15.	1.0	10
714	Renal cell tumors with an entrapped papillary component: a collision with predilection for oncocytic tumors. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 399-407.	3.0	10
715	Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications. <i>Modern Pathology</i> , 2021, 34, 1384-1391.	5.8	10
716	A genome-wide cross-trait analysis highlights the shared genetic structure between COVID-19 and Alzheimer's disease. <i>Journal of Infection</i> , 2022, 84, e1-e2.	3.4	10
717	CHARACTERIZATION AND PREDICTORS OF PROSTATE SPECIFIC ANTIGEN PROGRESSION RATES AFTER RADICAL RETROPUBIC PROSTATECTOMY. <i>Journal of Urology</i> , 2000, 164, 749-753.	3.9	10
718	Emerging Immunotargets and Immunotherapies in Prostate Cancer. <i>Current Drug Targets</i> , 2016, 17, 777-782.	2.3	10
719	Immunotherapy and Radiation Therapy in Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2020, 21, 1463-1475.	2.3	10
720	Nano-enhanced Optical Gene Delivery to Retinal Degenerated Mice. <i>Current Gene Therapy</i> , 2019, 19, 318-329.	2.1	10

#	ARTICLE	IF	CITATIONS
721	A comprehensive review of the analysis and integration of omics data for SARS-CoV-2 and COVID-19. <i>Briefings in Bioinformatics</i> , 2022, 23, .	6.6	10
722	Boosting the singlet oxygen production from H <sub>2</sub> O <sub>2</sub> activation with highly dispersed Co <sup>II</sup> -N-graphene for pollutant removal. <i>RSC Advances</i> , 2022, 12, 17864-17872.	3.7	10
723	Expression of OCT4 Transcription Factor in Cutaneous Neoplasia. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2007, 15, 359-362.	1.3	9
724	Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications. <i>Seminars in Diagnostic Pathology</i> , 2008, 25, 232-244.	2.3	9
725	How much do you know about benign, preneoplastic, non-invasive and invasive neoplastic lesions of the urinary bladder classified according to the 2004 WHO scheme?. <i>Diagnostic Pathology</i> , 2011, 6, 31.	2.1	9
726	The Importance of Interaction Between Urologists and Pathologists in Incidental Prostate Cancer Management. <i>European Urology</i> , 2011, 60, 75-77.	5.1	9
727	Critical analysis of the 2010 TNM classification in patients with lymph node <sup>+</sup> positive bladder cancer: Influence of lymph node disease burden. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1003-1009.	1.8	9
728	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 355-357.	2.6	9
729	Pathology and molecular updates in tumors of the prostate: towards a personalized approach. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 781-789.	3.4	9
730	Digital versus light microscopy assessment of surgical margin status after radical prostatectomy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 451-460.	3.0	9
731	Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications. <i>Frontiers in Genetics</i> , 2020, 11, 349.	2.4	9
732	pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 3-16.	3.0	9
733	Whipple disease: a 15-year retrospective study on 36 patients with positive polymerase chain reaction for <i>Tropheryma whippelii</i> . <i>Clinical Microbiology and Infection</i> , 2021, 27, 910.e9-910.e13.	6.6	9
734	Predicting Future Cancer Burden in the United States By Artificial Neural Networks. <i>Future Oncology</i> , 2021, 17, 159-168.	2.4	9
735	Synthesis, crystal growth, characterization and DFT investigation of a nonlinear optically active cuminaldehyde derivative hydrazone. <i>Acta Crystallographica Section B: Structural Science, Crystal Engineering and Materials</i> , 2021, 77, 249-259.	1.2	9
736	Prostate Cancer in 2021: Novelty in Prognostic and Therapeutic Biomarker Evaluation. <i>Cancers</i> , 2021, 13, 3471.	3.9	9
737	Sustained and enhanced anaerobic removal of COD and nitrogen in a zeolite amended glycogen accumulating organism dominated biofilm process. <i>Science of the Total Environment</i> , 2022, 807, 150602.	8.2	9
738	Gene Transfer via Particle Bombardment: Applications of the Accell Gene Gun. , 1994, , 193-209.		9

#	ARTICLE	IF	CITATIONS
739	Cylindrical illumination with angular coupling for whole-prostate photoacoustic tomography. <i>Biomedical Optics Express</i> , 2019, 10, 1405.	3.0	9
740	Emerging Immunotargets in Bladder Cancer. <i>Current Drug Targets</i> , 2016, 17, 757-770.	2.3	9
741	Current androgen receptor antagonists under investigation for resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 191-202.	2.5	9
742	Artificial intelligence in prostate cancer: Definitions, current research, and future directions. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 262-270.	1.8	9
743	<sc>Lowâ€grade</sc> prostate cancer should still be labelled cancer. <i>BJU International</i> , 2022, 130, 741-743.	2.8	9
744	Radical prostatectomy as initial monotherapy for patients with pathologically confirmed highâ€grade prostate cancer. <i>BJU International</i> , 2010, 105, 1372-1376.	2.8	8
745	Clonality and<i>TP53</i>Mutation Analysis of Focal Nodular Hyperplasia of the Liver. <i>American Journal of Clinical Pathology</i> , 2010, 134, 65-70.	0.8	8
746	Lymphadenectomy in Urologic Oncology: Pathologic Considerations. <i>Urologic Clinics of North America</i> , 2011, 38, 483-495.	2.0	8
747	Combined handling of prostate base/bladder neck and seminal vesicles in radical prostatectomy specimens: our approach with the whole mount technique. <i>Histopathology</i> , 2013, 63, 431-435.	3.1	8
748	Clear cell renal cell carcinoma with intratumoral and nodal extramedullary megakaryopoiesis: a potential diagnostic pitfall. <i>Human Pathology</i> , 2014, 45, 1306-1309.	2.4	8
749	A Better Understating of the Morphological Features and Molecular Characteristics of Intraductal Carcinoma Helps Clinicians Further Explain Prostate Cancer Aggressiveness. <i>European Urology</i> , 2015, 67, 504-507.	5.1	8
750	High fidelity of driver chromosomal alterations among primary and metastatic renal cell carcinomas: implications for tumor clonal evolution and treatment. <i>Modern Pathology</i> , 2016, 29, 1347-1357.	5.8	8
751	Mixed germ cellâ€sex cord stromal tumor of the testis with an intratubular component: a problem in differential diagnosis. <i>Human Pathology</i> , 2016, 51, 51-56.	2.4	8
752	Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017, 25, 39-43.	1.3	8
753	Novel ECG parameters are strongly associated with inflammatory 18 F-FDG PET findings in patients with suspected cardiac sarcoidosis. <i>International Journal of Cardiology</i> , 2017, 249, 454-460.	1.7	8
754	Clinicopathological implications to micropapillary bladder urothelial carcinoma of the presence of sialyl Lewis X-decorated mucin 1 in stroma-facing membranes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 606.e17-606.e23.	1.8	8
755	Quantitative Image Analysis on Histologic Virtual Slides for Prostate Pathology Diagnosis, Response to Chemopreventive Agents, and Prognosis. <i>European Urology Focus</i> , 2017, 3, 467-469.	3.4	8
756	A novel method to identify pre-microRNA in various species knowledge base on various species. <i>Journal of Biomedical Semantics</i> , 2017, 8, 30.	1.6	8

#	ARTICLE	IF	CITATIONS
757	Profile of consumers and their partners of a perinatal and infant mental health (PIMH) service in Australia. <i>Health and Social Care in the Community</i> , 2018, 26, e154-e163.	1.7	8
758	Upper urinary tract urothelial carcinoma and its variants: transition from morphology to personalized molecular characterization in diagnosis, prognosis, and therapy. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 1021-1028.	3.4	8
759	Proof of concept of wastewater treatment via passive aeration SND using a novel zeolite amended biofilm reactor. <i>Water Science and Technology</i> , 2018, 78, 2204-2213.	2.5	8
760	Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721881537.	2.1	8
761	Utility of Sry-Related HMG-Box Gene 10 (SOX10) as a marker of melanoma in effusion cytology. <i>Diagnostic Cytopathology</i> , 2019, 47, 653-658.	1.2	8
762	Fluorescence In Situ Hybridization for the X and Y Chromosome Centromeres Helps Differentiate Between Gestational and Nongestational Choriocarcinoma in Clinically Ambiguous Cases. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 863-868.	2.6	8
763	Urologists During the COVID-19 Pandemic: What Can Be Learned in Terms of Social Interaction, Visibility, and Social Distance. <i>European Urology</i> , 2020, 78, 478-481.	5.1	8
764	Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. <i>Cells</i> , 2020, 9, 1495.	4.3	8
765	Immunophenotypic and pathologic heterogeneity of unclassified renal cell carcinoma: a study of 300 cases. <i>Human Pathology</i> , 2020, 102, 70-78.	2.4	8
766	Outcomes comparison of hydrophilic and non-hydrophilic catheters for patients with intermittent catheterization: An updated meta-analysis. <i>Asian Journal of Surgery</i> , 2020, 43, 633-635.	0.5	8
767	Social Influences on Binge Drinking in Emerging Adults: Which Social Network Members Matter Most?. <i>Substance Abuse</i> , 2020, 41, 480-484.	2.5	8
768	Transforming Pt-SnO <sub>2</sub> Nanoparticles into Pt-SnO <sub>2</sub> Composite Nanoceramics for Room-Temperature Hydrogen-Sensing Applications. <i>Materials</i> , 2021, 14, 2123.	3.0	8
769	Incidental Prostate Cancer (cT1a-cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines. <i>European Urology Oncology</i> , 2022, 5, 256-258.	6.2	8
770	Colorectal cancer with microsatellite instability: Right-sided location and signet ring cell histology are associated with nodal metastases, and extranodal extension influences disease-free survival. <i>Pathology Research and Practice</i> , 2021, 224, 153519.	2.3	8
771	A pyramidal deep learning pipeline for kidney whole-slide histology images classification. <i>Scientific Reports</i> , 2021, 11, 20189.	3.5	8
772	<i>BIN1</i> rs744373 located in enhancers of brain tissues upregulates <i>BIN1</i> mRNA expression, thereby leading to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1587-1588.	0.7	8
773	Preparation and Characterization of Multi-Doped Porous Carbon Nanofibers from Carbonization in Different Atmospheres and Their Oxygen Electrocatalytic Properties Research. <i>Nanomaterials</i> , 2022, 12, 832.	4.2	8
774	Lymphocytic vasculitis of the prostate transition zone. <i>BJU International</i> , 2012, 110, 1775-1780.	2.8	7

#	ARTICLE	IF	CITATIONS
775	A low grade PIN-like neoplasm of the transition zone immunohistochemically negative for basal cell markers: a possible example of low grade adenocarcinoma with stratified epithelium. <i>Pathology</i> , 2014, 46, 88-91.	0.7	7
776	Expression of Transcription Factors and Nuclear Receptors in Mixed Germ Cell-Sex Cord Stromal Tumor and Related Tumors of the Gonads. <i>International Journal of Gynecological Pathology</i> , 2015, 34, 528-534.	1.6	7
777	Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report. <i>Human Pathology</i> , 2015, 46, 1040-1044.	2.4	7
778	Studying Dynamic Features in Myocardial Infarction Progression by Integrating miRNA-Transcription Factor Co-Regulatory Networks and Time-Series RNA Expression Data from Peripheral Blood Mononuclear Cells. <i>PLoS ONE</i> , 2016, 11, e0158638.	2.4	7
779	Multiple and bilateral kidney tumors with clear cells of three different histotypes: A case report with clinicopathologic and molecular study. <i>Apmis</i> , 2016, 124, 619-623.	2.0	7
780	Re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. <i>Eur Urol</i> 2015;68:912-4. <i>European Urology</i> , 2016, 70, e72-e74.	5.1	7
781	Grenfell Tower fire – a tragic case study in health inequalities. <i>British Dental Journal</i> , 2017, 223, 478-480.	1.0	7
782	Cyclic hydrostatic pressure promotes uroplakin expression in human urothelial cells through activation of ERK1/2 signaling. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 2499-2503.	2.2	7
783	Loss of ARID1A expression is associated with DNA mismatch repair protein deficiency and favorable prognosis in advanced stage surgically resected esophageal adenocarcinoma. <i>Human Pathology</i> , 2019, 94, 1-10.	2.4	7
784	Detection of androgen receptor (AR) and AR-V7 in small cell prostate carcinoma: Diagnostic and therapeutic implications. <i>Asian Journal of Urology</i> , 2019, 6, 109-113.	1.3	7
785	Prostate cancer pathology: What has changed in the last 5 years. <i>Urologia</i> , 2020, 87, 3-10.	0.7	7
786	The Utility of ERBB4 and RB1 Immunohistochemistry in Distinguishing Chromophobe Renal Cell Carcinoma From Renal Oncocytoma. <i>International Journal of Surgical Pathology</i> , 2020, 28, 259-264.	0.9	7
787	New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?. <i>Cells</i> , 2020, 9, 1522.	4.3	7
788	The expanding molecular and mutational landscape of nested variant of urothelial carcinoma. <i>Histopathology</i> , 2020, 76, 638-639.	3.1	7
789	Immunoexpression of bone resorption biomarkers in apical periodontitis in diabetics and normoglycaemics. <i>International Endodontic Journal</i> , 2020, 53, 1025-1032.	5.3	7
790	Role of Neoadjuvant Chemotherapy in Squamous Variant Histology in Urothelial Bladder Cancer: Does Presence and Percentage Matter?. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 47-52.	1.9	7
791	Grading of Chromophobe Renal Cell Carcinoma: Do We Need It?. <i>European Urology</i> , 2021, 79, 232-233.	5.1	7
792	Uterus transplantation for fertility preservation in patients with gynecologic cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 371-378.	2.9	7



#	ARTICLE	IF	CITATIONS
793	Digital diagnostics and artificial intelligence in prostate cancer treatment in 5 years from now. <i>Translational Andrology and Urology</i> , 2021, 10, 1499-1505.	1.4	7
794	TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?â€”a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 1541-1552.	1.4	7
795	Neoplasms of the kidney. , 2008, , 76-171.		7
796	Liquid Biopsies in the Management of Bladder Cancer: Next-Generation Biomarkers for Diagnosis, Surveillance, and Treatment-Response Prediction. <i>Critical Reviews in Oncogenesis</i> , 2017, 22, 389-401.	0.4	7
797	Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?. <i>Current Drug Metabolism</i> , 2017, 18, 692-699.	1.3	7
798	Highly dispersed and stable nano zero-valent iron doped electrospun carbon nanofiber composite for aqueous hexavalent chromium removal. <i>RSC Advances</i> , 2022, 12, 8178-8187.	3.7	7
799	Integrative characterization of intraductal tubulopapillary neoplasm (ITPN) of the pancreas and associated invasive adenocarcinoma. <i>Modern Pathology</i> , 2022, 35, 1929-1943.	5.8	7
800	Precision Medicine in Bladder Cancer: Present Challenges and Future Directions. <i>Journal of Personalized Medicine</i> , 2023, 13, 756.	2.6	7
801	Fas-Fas ligand signaling pathway mediates an interleukin-12-induced rejection of a murine prostate tumor system. <i>Prostate</i> , 2002, 53, 69-76.	2.3	6
802	Perivascular Epithelioid Cell Tumor of the Bladder. <i>Journal of Urology</i> , 2011, 185, 1473-1474.	3.9	6
803	Recurrent papillary urothelial neoplasm of low malignant potential. Subtle architectural disorder detected by quantitative analysis in DAXX-immunostained tissue sections. <i>Human Pathology</i> , 2014, 45, 745-752.	2.4	6
804	Immunotargeting and Personalized Therapies in Genitourinary Cancers. <i>Future Oncology</i> , 2016, 12, 1853-1856.	2.4	6
805	Activity and Functions of Tumor-associated Macrophages in Prostate Carcinogenesis. <i>European Urology Supplements</i> , 2017, 16, 301-308.	0.5	6
806	<i>TMPRSS2-ERG</i> gene fusion is rare compared to <i>PTEN</i> deletions in stage T1a prostate cancer. <i>Molecular Carcinogenesis</i> , 2017, 56, 814-820.	2.9	6
807	Re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. <i>Eur Urol</i> 2016;70:738â€”9. <i>European Urology</i> , 2017, 71, e73-e75.	5.1	6
808	Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma. <i>Journal of Clinical Pathology</i> , 2018, 71, 467-471.	2.2	6
809	Vasitis nodosa and related lesions: a modern immunohistochemical staining profile with special emphasis on novel diagnostic dilemmas. <i>Human Pathology</i> , 2018, 73, 164-170.	2.4	6
810	Biological Issues with Cabozantinib in Bone Metastatic Renal Cell Carcinoma and Castration-Resistant Prostate Cancer. <i>Future Oncology</i> , 2018, 14, 2559-2564.	2.4	6



#	ARTICLE	IF	CITATIONS
811	Re: Gillian Vandekerckhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. <i>Eur Urol</i> 2019;75:667-75. <i>European Urology</i> , 2019, 76, e69-e72.	5.1	6
812	Designing Novel Immunocombinations in Metastatic Renal Cell Carcinoma. <i>Immunotherapy</i> , 2020, 12, 1257-1268.	2.1	6
813	Healthy ageing in a deprived northern UK city: A co-creation study. <i>Health and Social Care in the Community</i> , 2020, 28, 2233-2242.	1.7	6
814	Prostate cancer grading, time to go back to the future. <i>BJU International</i> , 2021, 127, 165-168.	2.8	6
815	Intraductal carcinoma of the prostate is not a diagnostic entity. <i>Histopathology</i> , 2021, 78, 342-344.	3.1	6
816	US-Guided Transforaminal Cervical Nerve Root Block: A Novel Lateral in-Plane Approach. <i>Pain Medicine</i> , 2021, 22, 1940-1945.	2.0	6
817	Room-Temperature Hydrogen-Sensing Capabilities of Pt-SnO <sub>2</sub> and Pt-ZnO Composite Nanoceramics Occur via Two Different Mechanisms. <i>Nanomaterials</i> , 2021, 11, 504.	4.2	6
818	Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. <i>European Urology</i> , 2021, 79, 489-491.	5.1	6
819	Noninvasive papillary urothelial neoplasia (NIPUN): Renaming cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 286-290.	1.8	6
820	Clear cell papillary renal cell carcinoma: Characteristics and survival outcomes from a large single institutional series. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 370.e21-370.e25.	1.8	6
821	Decoding Neural Activity in Sulcal and White Matter Areas of the Brain to Accurately Predict Individual Finger Movement and Tactile Stimuli of the Human Hand. <i>Frontiers in Neuroscience</i> , 2021, 15, 699631.	3.0	6
822	Template-driven construction of [8]-imidazolium macrocycles. <i>Organic Chemistry Frontiers</i> , 2021, 8, 1431-1436.	4.6	6
823	Fluorescence In Situ Hybridization (FISH) Detection of Chromosomal 12p Anomalies in Testicular Germ Cell Tumors. <i>Methods in Molecular Biology</i> , 2021, 2195, 49-63.	1.4	6
824	Analysis of Protein-Protein Interaction Networks through Computational Approaches. <i>Protein and Peptide Letters</i> , 2020, 27, 265-278.	0.9	6
825	Molecular Characterization of Testicular Germ Cell Tumors Using Tissue Microdissection. <i>Methods in Molecular Biology</i> , 2021, 2195, 31-47.	1.4	6
826	Removal of Chromium(VI) by Nanoscale Zero-Valent Iron Supported on Melamine Carbon Foam. <i>Nanomaterials</i> , 2022, 12, 1866.	4.2	6
827	Radical prostatectomy specimen processing: A critical appraisal of sampling methods. <i>Current Diagnostic Pathology</i> , 2007, 13, 490-498.	0.5	5
828	Re: Peripheral Zone Prostate Cancers: Location and Intraprostatic Patterns of Spread at Histopathology. <i>European Urology</i> , 2010, 58, 180-182.	5.1	5

#	ARTICLE	IF	CITATIONS
829	Re: Antibody-drug Conjugates Targeting Prostate-specific Membrane Antigen. <i>European Urology</i> , 2014, 66, 1190-1193.	5.1	5
830	Precision Medicine in Colorectal Cancer: Evolving Genomic Landscape and Emerging Consensus. <i>Future Oncology</i> , 2015, 11, 2711-2719.	2.4	5
831	Prostate Cancer Glands with Cribriform Architecture and with Glomeruloid Features should be Considered as Gleason Pattern 4 and not Pattern 3. <i>Future Oncology</i> , 2016, 12, 1431-1433.	2.4	5
832	Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 479-486.	1.9	5
833	Unclassified Renal Cell Carcinoma With Significant Response to Nivolumab. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e517-e519.	1.9	5
834	Müllerian Adenosarcoma of the Urinary Bladder: Clinicopathologic and Immunohistochemical Features With Novel Genetic Aberrations. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1007-e1014.	1.9	5
835	Preservation of truncal genomic alterations in clear cell and papillary renal cell carcinomas with sarcomatoid features: An intra- and intertumoral, multifocal fluorescence in situ hybridization analysis reveals limited genetic heterogeneity. <i>Molecular Carcinogenesis</i> , 2017, 56, 2527-2537.	2.9	5
836	<i>Actinomyces radidentis</i> and <i>Actinomyces haliotis</i> , coccoid <i>Actinomyces</i> species isolated from the human oral cavity. <i>Anaerobe</i> , 2017, 48, 19-26.	2.2	5
837	Unclassified hemangioma-like renal cell carcinoma: a potential diagnostic pitfall. <i>Human Pathology</i> , 2018, 75, 132-136.	2.4	5
838	From Gleason Grading System and High-grade Tertiary Patterns to Grade Groups and Integrated Quantitative Gleason Score. <i>European Urology</i> , 2018, 73, 684-686.	5.1	5
839	Can tumor-associated macrophages in ductal carcinoma in situ on biopsy predict invasive carcinoma on excision?. <i>Human Pathology</i> , 2018, 82, 158-162.	2.4	5
840	Immunohistochemical characteristics of renomedullary interstitial cell tumor: a study of 41 tumors with emphasis on differential diagnosis of mesenchymal neoplasms. <i>Human Pathology</i> , 2018, 82, 46-50.	2.4	5
841	Molecular evidence supporting the precursor nature of atypical adenomatous hyperplasia of the prostate. <i>Molecular Carcinogenesis</i> , 2019, 58, 1272-1278.	2.9	5
842	Liquid biopsies in urological cancers: what we need to know before starting using them. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 135-139.	3.4	5
843	An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 207-217.	3.4	5
844	Practical Molecular Testing in a Clinical Genitourinary Service. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 277-289.	2.6	5
845	Gonadoblastoma versus ovarian mixed germ cell-sex cord stromal tumor in women or girls with no evidence of a disorder of sex development: A problem in differential diagnosis. <i>Pathology Research and Practice</i> , 2020, 216, 153198.	2.3	5
846	Duodenal gangliocytic paraganglioma: A very rare cause for upper gastrointestinal bleeding: Case report with review of literature. <i>International Journal of Surgery Case Reports</i> , 2020, 75, 408-412.	0.6	5

#	ARTICLE	IF	CITATIONS
847	Chromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One. <i>European Urology Oncology</i> , 2021, 4, 331-333.	6.2	5
848	Clinical Considerations and Prognosis of Well-Differentiated Neuroendocrine Tumor Occurring Within a Renal Teratoma—A Case Series. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e72-e77.	1.9	5
849	Invasive poorly differentiated adenocarcinoma of the bladder following augmentation cystoplasty: a multi-institutional clinicopathological study. <i>Pathology</i> , 2021, 53, 214-219.	0.7	5
850	Multitarget fluorescence in situ hybridization diagnostic applications in solid and hematological tumors. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 161-173.	3.4	5
851	Lesson from the COVID-19 pandemic: pathologists need to build their confidence on working in a digital microscopy environment. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 227-229.	3.0	5
852	Lactiplantibacillus plantarum Reduced Renal Calcium Oxalate Stones by Regulating Arginine Metabolism in Gut Microbiota. <i>Frontiers in Microbiology</i> , 2021, 12, 743097.	3.6	5
853	Implications of Cancer Stem Cells for Cancer Therapy. , 2009, , 255-262.		5
854	Identification of a Combined RNA Prognostic Signature in Adenocarcinoma of the Lung. <i>Medical Science Monitor</i> , 2019, 25, 3941-3956.	1.2	5
855	PD-L1 Inhibitors for the Treatment of Prostate Cancer. <i>Current Drug Targets</i> , 2020, 21, 1558-1565.	2.3	5
856	Update on Prostate Cancer Diagnosis, Prognosis, and Prediction to Response to Therapy. <i>Cells</i> , 2021, 10, 20.	4.3	5
857	The Effect of Health Education Combined with Personalized Psychological Nursing Intervention on Pregnancy Outcome of Pregnant Women with Gestational Diabetes Mellitus. <i>BioMed Research International</i> , 2022, 2022, 1-6.	2.0	5
858	Enhancing splitting tensile strength of biocarbonated reactive magnesia-based sand using polypropylene fiber reinforcement. <i>Acta Geotechnica</i> , 2022, 17, 4761-4768.	5.7	5
859	A Novel Bitcoin and Gold Prices Prediction Method Using an LSTM-P Neural Network Model. <i>Computational Intelligence and Neuroscience</i> , 2022, 2022, 1-12.	1.8	5
860	Clinicopathologic and Immunohistochemical Characterization of Sarcomatoid Chromophobe Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2022, 46, 1171-1179.	4.0	5
861	Morphologic spectrum of treatment-related changes in prostate tissue and prostate cancer: an updated review. <i>Human Pathology</i> , 2022, 127, 56-66.	2.4	5
862	Pleomorphic giant cell carcinoma of the prostate: clinicopathologic analysis and oncological outcomes. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2023, 482, 493-505.	3.0	5
863	Harnessing artificial intelligence for prostate cancer management. <i>Cell Reports Medicine</i> , 2024, 5, 101506.	6.0	5
864	Prostate cancer: towards the standardization and synthesis of morphology, genetics, and prognosis. <i>Histopathology</i> , 2012, 60, 1-3.	3.1	4

#	ARTICLE	IF	CITATIONS
865	Laser Capture Microdissection in Molecular Diagnostics. , 2013, , 465-482.		4
866	Pathology of flat bladder lesions with emphasis on putative precursors. Diagnostic Histopathology, 2013, 19, 355-365.	0.5	4
867	Paraganglion cells stain positively for <sc>OCT</sc>4: a potential pitfall in assessing retroperitoneal lymph node dissection specimens for germ cell tumour metastasis. Histopathology, 2013, 62, 360-363.	3.1	4
868	Somatostatin receptor expression in prostate carcinoma: the urological pathologist's role in the era of personalised medicine. Pathology, 2013, 45, 93-96.	0.7	4
869	Les tumeurs rÃ©nales: recommandations de la confÃ©rence de consensus de lâ€™International Society of Urologic Pathology (ISUP) 2012. Annales De Pathologie, 2014, 34, 448-461.	0.2	4
870	Is <sc>ALK</sc> gene rearrangement overlooked in primary gastrointestinal <sc>T</sc> cell lymphomas? About two cases. Pathology International, 2015, 65, 666-670.	1.4	4
871	Three-Tiered Nodal Classification System for Bladder Cancer: A New Proposal. Future Oncology, 2015, 11, 399-408.	2.4	4
872	Oncologic and quality-of-life outcomes with wide resection in robot-assisted laparoscopic radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 70.e9-70.e14.	1.8	4
873	Editorial (Thematic Issue: Emerging Immunotargets in Genitourinary Tumors). Current Drug Targets, 2016, 17, 748-749.	2.3	4
874	Clinical impact of tumoral angiogenesis on renal cell carcinoma management: where do we stand?. Expert Review of Precision Medicine and Drug Development, 2016, 1, 229-231.	0.6	4
875	Activity of Chemokines in Prostate and Renal Tumors and their Potential Role as Future Therapeutic Targets. Future Oncology, 2017, 13, 1105-1114.	2.4	4
876	Congenital capillary proliferation of the kidney: a distinctive renal vascular lesion of childhood. Human Pathology, 2017, 66, 59-66.	2.4	4
877	Reply to Chou et al "Do significant TFE3 gene rearrangements occur in succinate dehydrogenase deficient renal cell carcinoma? Borderline FISH results should be interpreted with caution" Mod Pathol 2017; in press.. Modern Pathology, 2017, 30, 1509-1511.	5.8	4
878	Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View. European Urology Supplements, 2017, 16, 223-231.	0.5	4
879	Use of CD42b immunohistochemical stain for the detection of Histoplasma. Annals of Diagnostic Pathology, 2018, 32, 47-50.	1.4	4
880	Clinicopathological characteristics of ypT0N0 urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. Journal of Clinical Pathology, 2019, 72, 550-553.	2.2	4
881	Editorial: Emerging Biomarkers in Genitourinary Tumors. Frontiers in Oncology, 2019, 9, 326.	3.0	4
882	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. Expert Review of Cardiovascular Therapy, 2019, 17, 917-927.	1.6	4

#	ARTICLE	IF	CITATIONS
883	Neoplasms of the Urinary Bladder. , 2020, , 230-321.e19.		4
884	<i>ProteinFishing</i>: a protein complex generator within the ModelX toolsuite. Bioinformatics, 2020, 36, 4208-4210.	4.2	4
885	Re: Multi-institutional Re-evaluation of Prognostic Factors in Chromophobe Renal Cell Carcinoma: Proposal of a Novel Two-tiered Grading Scheme. European Urology, 2020, 78, 114-116.	5.1	4
886	Gonadoblastoma in individuals with a normal karyotype and no evidence of a disorder of sex development. Pathology, 2020, 52, 605-607.	0.7	4
887	Molecular diagnostics in uro-oncology. Expert Review of Molecular Diagnostics, 2020, 20, 117-121.	3.4	4
888	Exciting experiences in the â€˜Rocky road to digital diagnosticsâ€™. Journal of Clinical Pathology, 2021, 74, 5-6.	2.2	4
889	â€˜This place is not for children like herâ€™: disability, ambiguous belonging and the claiming of disadvantage in postapartheid South Africa. Medical Humanities, 2021, 47, 4-10.	1.2	4
890	Promising novel therapies for relapsed and refractory testicular germ cell tumors. Expert Review of Anticancer Therapy, 2021, 21, 53-69.	2.5	4
891	Identification of Gene Signature Associated with Type 2 Diabetes Mellitus by Integrating Mutation and Expression Data. Current Gene Therapy, 2021, 22, 51-58.	2.1	4
892	Metastatic urothelial carcinoma to the brain, spinal cord and spine: A contemporary multi-institutional clinicopathologic analysis of 24 cases. Pathology Research and Practice, 2021, 224, 153537.	2.3	4
893	Adrenal Myelolipoma: 369 Cases From a High-Volume Center. Frontiers in Cardiovascular Medicine, 2021, 8, 663346.	2.5	4
894	The Multilayered Regulation of the Oncogenic Protein YY1. Critical Reviews in Oncogenesis, 2017, 22, 109-129.	0.4	4
895	Separation of the Epitopes in a Multi-Epitope Chimera: Helical or Flexible Linkers. Protein and Peptide Letters, 2020, 27, 604-613.	0.9	4
896	Granulomas associated with renal neoplasms: A multi-institutional clinicopathological study of 111 cases. Histopathology, 2022, 80, 922-927.	3.1	4
897	Predictors of in-hospital mortality in diabetic patients with non-ST-elevation myocardial infarction. Egyptian Heart Journal, 2022, 74, 20.	1.2	4
898	Risk Classification of Bladder Cancer by Gene Expression and Molecular Subtype. Cancers, 2023, 15, 2149.	3.9	4
899	Proteomic studies of Anaplasia in Wilms Tumor. Proteomics Insights, 2011, 4, PRI.S7466.	2.0	3
900	Schistosoma japonicum: Treatment of different developmental stages in mice with long-acting praziquantel implants. Experimental Parasitology, 2011, 129, 254-259.	1.2	3

#	ARTICLE	IF	CITATIONS
901	Squamous cysts arising from segmental renal dysplasia. <i>Pediatric Nephrology</i> , 2011, 26, 1893-1896.	1.8	3
902	Grading of Bladder Cancer. , 2012, , 161-191.		3
903	Immunotherapy of metastatic and autochthonous liver cancer with IL-15/IL-15R $\alpha$ fusion protein. <i>Oncolimmunology</i> , 2014, 3, e963409.	4.8	3
904	Urinary Bladder and Urachus. , 2015, , 421-437.		3
905	Calibration of a Novel, Laparoscopic, 12-mm, Ultrasound, Image-guided, High-intensity Focused Ultrasound Probe for Ablation of Renal Neoplasms. <i>Urology</i> , 2015, 85, 953-958.	1.4	3
906	Early detection of prostate cancer: can we have our cake and eat it too?. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 247-249.	2.5	3
907	Considerations for standardizing predictive molecular pathology for cancer prognosis. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 47-55.	3.4	3
908	Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View. <i>European Urology Supplements</i> , 2017, 16, 232-240.	0.5	3
909	Editorial: Emerging Biomarkers in Genitourinary Tumors. <i>Current Drug Metabolism</i> , 2017, 18, 690-691.	1.3	3
910	Perspective on cytorreduction and metastasis-directed therapy in node positive and metastatic urothelial carcinoma of the bladder. <i>Translational Andrology and Urology</i> , 2017, 6, 1117-1122.	1.4	3
911	PTEN Expression in Mucinous Prostatic Adenocarcinoma, Prostatic Adenocarcinoma With Mucinous Features, and Adjacent Conventional Prostatic Adenocarcinoma: A Multi-institutional Study of 92 Cases. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 225-230.	1.3	3
912	An ovulating follicle presenting as a testicular mass in a teenage patient with ovotesticular DSD. <i>Urology Case Reports</i> , 2018, 18, 26-28.	0.3	3
913	Re: Isabel Rauscher, Charlotte D $\ddot{u}$ rwel, Bernhard Haller, et al. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen $\alpha$ ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. <i>Eur Urol</i> 2018;73:656-61. <i>European Urology</i> . 2018. 74. e141-e144.	5.1	3
914	Prostate Cancer Grading: Are We Heading Towards Grade Grouping Version 2?. <i>European Urology</i> , 2019, 75, 32-34.	5.1	3
915	Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule. <i>Human Pathology</i> , 2019, 93, 6-15.	2.4	3
916	Digital versus light microscopy assessment of extraprostatic extension in radical prostatectomy samples. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 735-744.	3.0	3
917	Authors $\text{\textcircled{r}}$ reply to: Absence of the MA $\alpha$ P2K5 germline variants c.G961A and c.T1100C in a wide series of familial non $\alpha$ medullary thyroid carcinoma Italian families. <i>International Journal of Cancer</i> 2019; in press. <i>International Journal of Cancer</i> , 2019, 145, 601-602.	5.4	3
918	Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. <i>J Vasc Interv Radiol</i> 2018;29:589-97. <i>Eur Urol</i> 2018;74:525-6. <i>European Urology</i> , 2019, 75, e110-e113.	5.1	3

#	ARTICLE	IF	CITATIONS
919	Neoplasms of the Prostate. , 2020, , 415-525.e42.		3
920	Evaluation of individual and cumulative sites of extrarenal tumor invasion in pT3a clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 42.e13-42.e18.	1.8	3
921	Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 850.e1-850.e7.	1.8	3
922	Formation, Growth, or Rupture of De Novo Intracranial Aneurysms: Long-Term Follow-up Study of Subarachnoid Hemorrhage Survivors. Neurosurgery, 2021, 89, 1104-1111.	1.3	3
923	Distal Tubular Hyperplasia. American Journal of Surgical Pathology, 2021, 45, 516-522.	4.0	3
924	Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?. Translational Andrology and Urology, 2021, 10, 1581-1587.	1.4	3
925	Highly differentiated follicular thyroid-type carcinoma of the ovary reconsidered. Journal of Clinical Pathology, 2021, 74, 553-557.	2.2	3
926	Somatic-Type Yolk Sac Tumor Arising as a Predominant Component of Bladder Urothelial Carcinoma. International Journal of Surgical Pathology, 2022, 30, 207-213.	0.9	3
927	Molecular Pathology of Kidney Tumors. , 2013, , 171-212.		3
928	Urinary Biomarkers for Prostate Cancer. Current Drug Metabolism, 2017, 18, 723-726.	1.3	3
929	Prostate Cancer Biomarkers: Current Status. Critical Reviews in Oncogenesis, 2017, 22, 253-269.	0.4	3
930	Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 189-190.	4.1	3
931	OntoSem: an Ontology Semantic Representation Methodology for Biomedical Domain. , 2020, , .		3
932	High-intensity focused ultrasound for the treatment of prostate cancer: assessing location of failure after focal therapy in prostate cancer and review of histological characteristics and clinicopathologic correlates after treatmentâ€”a 5-year experience. Human Pathology, 2022, 119, 79-84.	2.4	3
933	Deep Learningâ€”Based Classification of Epithelialâ€”Mesenchymal Transition for Predicting Response to Therapy in Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 782515.	3.0	3
934	The pathological and molecular genetic landscape of the hereditary renal cancer predisposition syndromes. Histopathology, 2022, 81, 15-31.	3.1	3
935	Carcinosarcoma, a Rare Malignant Neoplasm of the Pancreas. Current Oncology, 2021, 28, 5295-5303.	2.3	3
936	Molecular simulation of enhanced separation of humid air components using GOâ€”PVA nanocomposite membranes under differential pressures. Physical Chemistry Chemical Physics, 2022, 24, 16442-16452.	2.9	3



#	ARTICLE	IF	CITATIONS
937	Histopathology of Prostate Cancer and its Precursors. Applied Immunohistochemistry and Molecular Morphology, 2023, 31, 467-477.	1.3	3
938	Oncofetal protein glypicanâ€³ is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer. Journal of Pathology, 2023, 260, 43-55.	4.5	3
939	Editorial Comment on: Prediction of Progression of Nonâ€“Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study. European Urology, 2008, 54, 843-844.	5.1	2
940	Neural Neoplasms of the Bladder. Journal of Urology, 2010, 184, 1492-1493.	3.9	2
941	Bladder Cancer: General Features. , 2012, , 137-159.		2
942	Urothelial Carcinoma in Situ. , 2012, , 113-136.		2
943	Pathological issues in biopsy specimens of men with prostate cancer eligible for active surveillance. Archivio Italiano Di Urologia Andrologia, 2014, 86, 314.	0.9	2
944	qPCR Is a Sensitive and Rapid Method for Detection of Cytomegaloviral DNA in Formalin-fixed, Paraffin-embedded Biopsy Tissue. Journal of Visualized Experiments, 2014, , .	0.3	2
945	Effects of tertiary Gleason pattern 5 on oncological outcome. Nature Reviews Urology, 2015, 12, 188-189.	3.9	2
946	Testis and Paratesticular Tissues. , 2015, , 465-480.		2
947	Does Squamous Differentiation Portend Worse Outcomes in Urothelial Bladder Cancer?. Urology Practice, 2015, 2, 335-342.	0.5	2
948	Genitourinary Cancers: Molecular Determinants for Personalized Therapies. Urologia, 2016, 83, 107-109.	0.7	2
949	BLAT2DOLite: An Online System for Identifying Significant Relationships between Genetic Sequences and Diseases. PLoS ONE, 2016, 11, e0157274.	2.4	2
950	DisSetSim: An online system for calculating similarity between disease sets. , 2016, , .		2
951	InfDisSim: A novel method for measuring disease similarity based on information flow. , 2016, , .		2
952	Synchronous clear cell renal cell carcinoma and multilocular cystic renal cell neoplasia of low malignant potential: A clinico-pathologic and molecular study. Pathology Research and Practice, 2016, 212, 471-474.	2.3	2
953	Letter to the Editor re: Iczkowski's Letter to the Editor re: Re: Rodolfo Montironi, Silvia Gasparini, Roberta Mazzucchelli, et al's Letter to the Editor re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. Eur Urol 2016;70:738â€“9: Sentinel Lymph Nodes in Adipose Tissue Surrounding the Prostate Gland and Seminal Vesicles as Observed in Virtual Whole-mount Histologic Slides. Eur Urol 2017;71:e73â€“5. European Urology, 2017, 72, e37-e38.	5.1	2
954	Clinical Trials for Specific Renal Cancer Subtypesâ€“The Time Will Come!. European Urology Supplements, 2017, 16, 241-252.	0.5	2

#	ARTICLE	IF	CITATIONS
955	Immunotherapy in genitourinary cancers: where are we going?. Expert Review of Precision Medicine and Drug Development, 2017, 2, 73-78.	0.6	2
956	A Closure Study of Total Scattering Using Airborne In Situ Measurements from the Winter Phase of TCAP. Atmosphere, 2018, 9, 228.	2.3	2
957	Fine-needle aspiration cytology of metastatic spindle cell follicular thyroid carcinoma: A case report. Diagnostic Cytopathology, 2019, 47, 608-611.	1.2	2
958	Neoplasms of the Kidney. , 2020, , 83-163.e23.		2
959	Renal Volume Loss During Partial Nephrectomy Due to Resected Healthy Parenchyma: A Tool for Quick Estimation. Journal of Endourology, 2020, 34, 856-861.	2.3	2
960	Prelplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness. International Journal of Biological Markers, 2020, 35, 82-90.	1.9	2
961	Predictors of Prostate-specific Membrane Antigen (PSMA/FOLH1) Expression in a Genomic Database. Urology, 2020, 144, 117-122.	1.4	2
962	A novel estimator of between-study variance in random-effects models. BMC Genomics, 2020, 21, 149.	2.9	2
963	Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States. Translational Andrology and Urology, 2021, 10, 1562-1568.	1.4	2
964	An update on immunotherapy in uro-oncology. Expert Review of Precision Medicine and Drug Development, 2021, 6, 229-233.	0.6	2
965	Renal oncocytoma with adverse pathologic features: a clinical and pathologic study of 50 cases. Modern Pathology, 2021, 34, 1947-1954.	5.8	2
966	Speed-accelerating method for the control of mobile chaotic agents. European Physical Journal: Special Topics, 2021, 230, 2043-2049.	2.6	2
967	Briefings in functional genomics special section editorial: analysis of integrated multiple omics data. Briefings in Functional Genomics, 2021, 20, 196-197.	2.8	2
968	Digital whole mount sections of the prostate: heading towards new ways of communicating with clinicians and patients without microscope. Minerva Urology and Nephrology, 2022, 74, .	2.9	2
969	Prioritizing Disease-Related Microbes Based on the Topological Properties of a Comprehensive Network. Frontiers in Microbiology, 2021, 12, 685549.	3.6	2
970	Longitudinal bidirectional associations between internalizing mental disorders and cardiometabolic disorders in the general adult population. Social Psychiatry and Psychiatric Epidemiology, 2021, 56, 1611-1621.	3.4	2
971	p53 Protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cancer, 1999, 85, 1293-1299.	4.1	2
972	Urothelial papilloma of the bladder. Cancer, 1999, 86, 2098-2101.	4.1	2

#	ARTICLE	IF	CITATIONS
973	Flat intraepithelial lesions of the urinary bladder. <i>Cancer</i> , 2000, 88, 625-631.	4.1	2
974	The Pathology of Prostate Cancer. , 2010, , 45-83.		2
975	Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians. <i>Asian Journal of Andrology</i> , 2019, 21, 19.	1.9	2
976	Mixed epithelial and stromal tumours of the kidney with malignant transformation: a clinicopathological study of four cases. <i>Pathology</i> , 2022, 54, 707-720.	0.7	2
977	Tumour grading: communication is the key. <i>Journal of Clinical Pathology</i> , 2023, 76, 291-292.	2.2	2
978	Multimodal Approach in the Diagnosis of Urologic Malignancies: Critical Assessment of ChatGPT-4V's Image-Reading Capabilities. <i>JCO Clinical Cancer Informatics</i> , 2024, , .	2.3	2
979	Grade 1 Urothelial Carcinoma Versus PUNLMP. <i>AJSP Review and Reports</i> , 2008, 13, 144-148.	0.1	1
980	Editorial Comment on: Prevalence of a Tertiary Gleason Grade and Its Impact on Adverse Histopathologic Parameters in a Contemporary Radical Prostatectomy Series. <i>European Urology</i> , 2009, 55, 402.	5.1	1
981	“No Pay, No Play” or From “Defensive or Passive Pathology” to “Active, Clinically Oriented Pathology”. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 1474-1475.	2.6	1
982	Stage pT1 Urothelial Carcinoma. , 2012, , 193-215.		1
983	Inflammatory and Infectious Conditions. , 2012, , 17-44.		1
984	Urothelial Metaplasia and Hyperplasia. , 2012, , 45-70.		1
985	Histologic Variants of Urothelial Carcinoma. , 2012, , 239-281.		1
986	Adenocarcinoma and Its Putative Precursors and Variants. , 2012, , 283-203.		1
987	Bladder Tumors with Inverted Growth. , 2012, , 383-398.		1
988	Handling and Reporting of Bladder Specimens. , 2012, , 525-544.		1
989	Squamous Cell Carcinoma and Other Squamous Lesions. , 2012, , 305-321.		1
990	Treatment Effects. , 2012, , 507-523.		1

#	ARTICLE	IF	CITATIONS
991	Re: "No Pay, No Play": The End of Professional Ethics in Pathology?. <i>European Urology</i> , 2012, 61, 424-425.	5.1	1
992	Molecular Pathology of Urinary Bladder Cancer. , 2013, , 229-253.		1
993	Conceptual Evolution in Cancer Biology. , 2013, , 77-109.		1
994	Editorial (Mini-Thematic Issue: Morphological and Molecular Backgrounds for Personalized Therapies) <i>Tj ETQq0 0 0 ggBT /Overlock 10 Tf</i>	2.3	1
995	The Prostate and Seminal Vesicles. , 2015, , 195-310.		1
996	Pulmonary Adenocarcinoma with Combined <i>ALK</i> Translocation and Copy Number Gain: A Rare Case With Treatment Response. <i>Lung Cancer Management</i> , 2015, 4, 125-129.	1.6	1
997	Cysts and Epithelial Proliferations of the Testicular Collecting System. , 2016, , 171-189.		1
998	Re: Umberto Leone Roberti Maggiore, Simone Ferrero, Massimo Candiani, et al. Bladder Endometriosis: A Systematic Review of Pathogenesis, Diagnosis, Treatment, Impact on Fertility, and Risk of Malignant Transformation. <i>Eur Urol</i> 2017;71:790-807. <i>European Urology</i> , 2017, 72, e139-e141.	5.1	1
999	Re: Daniel M. Geynisman. Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features. <i>Eur Urol</i> 2015;68:912-4. <i>European Urology</i> , 2017, 71, e27-e28.	5.1	1
1000	Improving outcome and prognosis prediction in non-muscle invasive bladder cancer using a gene expression score. <i>Translational Andrology and Urology</i> , 2017, 6, 991-993.	1.4	1
1001	Predicting the biological behavior of non-muscle-invasive bladder cancer: from histology to molecular taxonomy. <i>Translational Andrology and Urology</i> , 2017, 6, 987-990.	1.4	1
1002	Isolated tumor cells in regional lymph nodes in patients with adenocarcinoma of the esophagogastric junction might represent part of true metastases. <i>Human Pathology</i> , 2019, 93, 90-96.	2.4	1
1003	Clinical Utility Versus Futility: A Tipping Point for Liquid Biopsies in Bladder Cancer. <i>Future Oncology</i> , 2019, 15, 3751-3753.	2.4	1
1004	Renal Pelvis and Ureter. , 2020, , 164-178.e4.		1
1005	Cystic Trophoblastic Tumor in a Primary Central Nervous System Post-Chemotherapy Germ Cell Tumor: The First Case Report. <i>International Journal of Surgical Pathology</i> , 2020, 28, 925-928.	0.9	1
1006	Renal Cell Carcinoma: genomic landscape and clinical implications. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 95-100.	0.6	1
1007	Re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. <i>Eur Urol</i> 2020;77:269-76. <i>European Urology</i> , 2021, 79, e17-e19.	5.1	1
1008	Herbicidal activity of <i>Beauveria</i> sp. from Tibetan Plateau biome against <i>Avena fatua</i> L.. <i>Biocontrol Science and Technology</i> , 2021, 31, 265-283.	1.5	1

#	ARTICLE	IF	CITATIONS
1009	A systematic review of interventions to link families with preschool children from healthcare services to community-based support. <i>Journal of Public Health</i> , 2021, 43, e224-e235.	2.0	1
1010	A visual uncertainty analytics approach for weather forecast similarity measurement based on fuzzy clustering. <i>Journal of Visualization</i> , 2021, 24, 317-330.	1.8	1
1011	Mixed germ cell-sex cord stromal tumour of the testis and ovary: comparison and contrast. <i>Pathology</i> , 2021, 53, 166-169.	0.7	1
1012	Reply to Rodolfo Montironi, Marina Scarpelli, Alessia Cimadamore, and Gregor Mikuz's Letter to the Editor re: Theo van der Kwast, Fredrik Liedberg, Peter C. Black, et al. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. <i>Eur Urol Focus</i> . In press. <a href="https://doi.org/10.1016/j.euf.2021.03.017">https://doi.org/10.1016/j.euf.2021.03.017</a> . Focus on Our Personal Recollections and Observations. <i>European Urology Focus</i> , 2022, 8, 885-886.	3.4	1
1013	The Coronavirus Disease 2019 (COVID-19) Pandemic's Impact on Social Interaction in Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1049-1050.	2.6	1
1014	Re: Bas W.G. van Rhijn, Anouk E. Hentschel, Johannes Brähler, et al. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. <i>Eur Urol Oncol</i> 2021;4:182-91. <i>European Urology Oncology</i> , 2021, 4, 671-673.	6.2	1
1015	Neoplasms of the Kidney. , 2007, , 281-340.		1
1016	The Seminal Vesicles and Ejaculatory Ducts. , 0, , 169-178.		1
1017	A Simplified Diagnostic Approach on TFE3 Gene Fusion-Associated Renal Cell Carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 132-134.	2.6	1
1018	Editorial: Omics Data Integration Towards Mining of Phenotype Specific Biomarkers in Cancers and Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 763447.	3.9	1
1019	Testis and Paratesticular Structures. , 2015, , 311-371.		1
1020	A framework for exploring associations between biomedical terms in PubMed. <i>Oncotarget</i> , 2017, 8, 103100-103107.	1.8	1
1021	Liquid biopsies in renal cell carcinoma with focus on epigenome analysis. <i>Annals of Translational Medicine</i> , 2019, 7, S194-S194.	1.7	1
1022	System Biology Methods and Tools for Pharmaceutical Design. <i>Current Pharmaceutical Design</i> , 2020, 26, 3047-3048.	1.9	1
1023	Does pathological sub stratification of T2 bladder cancer predict outcome in a contemporary pure urothelial carcinoma cohort?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 196.e11-196.e16.	1.8	1
1024	Artificial intelligence and prostate cancer: Advances and challenges. <i>Urologia</i> , 2021, , 039156032110624.	0.7	1
1025	Practical Immunohistochemistry of Prostate Cancer and Related Lesions. , 0, , 193-208.		1
1026	Atypical cartilage in type II germ cell tumors of the mediastinum show significantly different patterns of IDH1/2 mutations from conventional chondrosarcoma. <i>Modern Pathology</i> , 2022, 35, 1636-1643.	5.8	1

#	ARTICLE	IF	CITATIONS
1027	Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder. <i>Modern Pathology</i> , 2023, 36, 100151.	5.8	1
1028	Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2. <i>Modern Pathology</i> , 2024, 37, 100424.	5.8	1
1029	23 Role of Immunohistochemical Expression of OCT4 in Ovarian Dysgerminoma. <i>Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas</i> , 2005, 4, 493-498.	0.0	0
1030	Cytokeratin (AE1/AE3) in addition to Î±-methylacyl coenzyme A racemase (P504S), 34-beta-E12, and p63 stains in evaluation of surgical specimens after hormonal therapy for prostatic adenocarcinomaâ€™reply. <i>Human Pathology</i> , 2008, 39, 305-306.	2.4	0
1031	Polyps and Other Nonneoplastic Benign Conditions. , 2012, , 71-84.		0
1032	Sarcomatoid Carcinoma (Carcinosarcoma). , 2012, , 355-381.		0
1033	Congenital Disorders and Pediatric Neoplasms. , 2012, , 399-422.		0
1034	Pathology of the Urachus. , 2012, , 567-579.		0
1035	Pathology of Renal Pelvis, Ureter, and Urethra. , 2012, , 581-608.		0
1036	Molecular Determinants of Tumor Recurrence. , 2012, , 609-622.		0
1037	Urinary Cytology. , 2012, , 623-644.		0
1038	Evaluation of Hematuria and Urinalysis. , 2012, , 645-653.		0
1039	Normal Anatomy and Histology. , 2012, , 1-16.		0
1040	Benign Epithelial Tumors. , 2012, , 85-97.		0
1041	Staging of Bladder Cancer. , 2012, , 217-237.		0
1042	Flat Urothelial Lesions with Atypia and Urothelial Dysplasia. , 2012, , 99-112.		0
1043	Lymphoid and Hematopoietic Tumors. , 2012, , 461-469.		0
1044	Urothelial Carcinoma Following Augmentation Cystoplasty. , 2012, , 471-484.		0

#	ARTICLE	IF	CITATIONS
1045	Other Rare Tumors. , 2012, , 485-495.		0
1046	Secondary Tumors. , 2012, , 497-505.		0
1047	Urine-based Biomarkers. , 2012, , 655-678.		0
1048	Tissue-based Biomarkers. , 2012, , 679-706.		0
1049	Molecular Pathology of Bladder Cancer. , 2012, , 707-733.		0
1050	Clonality Analysis and Tumor of Unknown Primary: Applications in Modern Oncology and Surgical Pathology. , 2013, , 129-180.		0
1051	Reply to JÃ©rÃ©me Verine's Letter to the Editor re: Rodolfo Montironi, Marina Scarpelli, Liang Cheng, et al. Immunoglobulin G4-related Disease in Genitourinary Organs: An Emerging Fibroinflammatory Entity Often Misdiagnosed Preoperatively as Cancer. Eur Urol. In press. <a href="http://dx.doi.org/10.1016/j.eururo.2012.11.056">http://dx.doi.org/10.1016/j.eururo.2012.11.056</a> . European Urology. 2013. 64. e53-e54.	5.1	0
1052	Pediatric composite nodal marginal zone lymphoma and classical Hodgkin lymphoma. Journal of Hematopathology, 2014, 7, 171-175.	0.5	0
1053	A novel method to identify pre-microRNA in various species knowledge base. , 2016, , .		0
1054	Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. Eur Urol 2015;68:542-3. European Urology, 2016, 70, e69-e70.	5.1	0
1055	Re: Daniel E. Spratt, Hebert A. Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. Eur Urol 2017;71:37-43. European Urology, 2017, 71, e121-e122.	5.1	0
1056	TMPRSS2-ERG Fusion in an Uncommon Presentation of Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, e489-e491.	1.9	0
1057	Ultrastructure of pheochromocytoma: undescribed morphologic features. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 537-543.	3.0	0
1058	Identifying diseases-related metabolites based on network. , 2017, , .		0
1059	In reply to: letter to the editor entitled: primary pure lymphoepithelioma-like carcinoma of the ureter. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 561-562.	3.0	0
1060	Re: A Novel Tool for Predicting Extracapsular Extension During Graded Partial Nerve Sparing in Radical Prostatectomy. European Urology, 2018, 73, 978-980.	5.1	0
1061	2185 The effects of autoimmune inflammation on proliferation, differentiation, and androgen receptor signaling in adult prostate stem cells. Journal of Clinical and Translational Science, 2018, 2, 31-31.	0.7	0
1062	Quick steps toward precision medicine in renal cell carcinoma. Expert Review of Precision Medicine and Drug Development, 2018, 3, 283-285.	0.6	0



#	ARTICLE	IF	CITATIONS
1063	Perspectives of Lung Cancer Control and Molecular Prevention. <i>Future Oncology</i> , 2019, 15, 3527-3530.	2.4	0
1064	Cardiac imaging and circulating biomarkers for primary prevention in the era of precision medicine. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 299-308.	0.6	0
1065	â™,â™€ Clear Cell Tumors of the Kidney and the Gynecologic Tract. , 2019, , 173-188.		0
1066	â™,â™€ Transitional Cell Tumors of the Bladder. , 2019, , 254-273.		0
1067	â™,â™€ Squamotransitional Carcinoma and Transitional Cell Metaplasia of the Cervix and the Vagina, and Squamous Cell Carcinoma and Squamous Lesions of the Urinary Tract. , 2019, , 274-277.		0
1068	â™,â™€ Micropapillary Urothelial Carcinoma of the Bladder versus Gynecologic Tract Carcinomas with Micropapillary Features: Similarities and Differences. , 2019, , 278-282.		0
1069	â™,â™€ Pathology of the Female and Male Urethra. , 2019, , 285-303.		0
1070	Annual review issue. <i>Histopathology</i> , 2019, 74, 3-3.	3.1	0
1071	Re: Lorenzo Marconi, Thomas Stonier, Rafael Tourinho-Barbosa, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. <i>Eur Urol</i> 2019;76:27â€“30. <i>European Urology</i> , 2020, 77, e100-e102.	5.1	0
1072	Impact of lockdown measures in abating the COVID-19 pandemic: Lessons from Indiaâ€™s phased approach. <i>European Journal of Public Health</i> , 2020, 30, .	0.3	0
1073	Re: Maria Chiara Sighinolfi, Bernardo Roccoâ€™s Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. <a href="https://uroweb.org/guideline/prostate-cancer/">https://uroweb.org/guideline/prostate-cancer/</a> . <i>Eur Urol</i> 2019;76:871. <i>European Urology</i> , 2020, 77, e122-e127.	5.1	0
1074	Genitourinary Neoplasms. , 2021, , 233-244.		0
1075	Let us not forget about our past contributions to the field of prostatic neoplasms: To some extent what we value now was already there. <i>Pathology Research and Practice</i> , 2021, 219, 153377.	2.3	0
1076	The Wide Spectrum of Oncocytic Changes and Tumors in the Kidney: Splitting and Lumping. <i>Pathobiology</i> , 2021, 88, 323-326.	3.6	0
1077	Reply to Alessia Cimadamore, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironiâ€™s Letter to the Editor re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. <i>Eur Urol</i> 2021;79:489â€“91. <i>European Urology</i> , 2021, 79, e174-e175.	5.1	0
1078	Genetic and epigenetic regulation in neoplasms composed of both germ cells and sex cord elements. <i>Pathology Research and Practice</i> , 2021, 222, 153428.	2.3	0
1079	Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? <i>Eur Urol Oncol</i> . In press. <i>European Urology Oncology</i> , 2021, 5, 261-261.	6.2	0
1080	Incidentally discovered myelolipomatous adrenal adenomas, including six cases presenting with hypercortisolism. <i>Pathology Research and Practice</i> , 2021, 224, 153508.	2.3	0

#	ARTICLE	IF	CITATIONS
1081	Re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. <a href="https://doi.org/10.1016/j.eururo.2021.03.009">https://doi.org/10.1016/j.eururo.2021.03.009</a> . European Urology, 2021, 80, e81-e82.	5.1	0
1082	Molekularpathologie bei urologischen Tumoren. Der Pathologe, 2021, 42, 310-318.	0.7	0
1083	Loss of Heterozygosity in Bone Marrows of Patients with Iron-Deficiency Anemia.. Blood, 2006, 108, 4863-4863.	1.4	0
1084	Clonality Analysis in Modern Oncology and Surgical Pathology. , 2008, , 261-301.		0
1085	Metastasizing breast carcinoma to the brain: a clinicopathologic and immunohistochemical study of 14 matched pairs.. FASEB Journal, 2008, 22, 706.24.	0.5	0
1086	Renal Pelvis, Ureter, and Urethra. , 2011, , 1567-1579.		0
1087	Tumors and Tumor-Like Conditions of Urinary Bladder, Renal Pelvis, Ureter and Urethra. , 2015, , 63-194.		0
1088	Renal Tumors and Tumor-Like Conditions. , 2015, , 1-61.		0
1089	Renal Pelvis, Ureter, and Urethra. , 2016, , 1737-1750.		0
1090	Human Disease-Protein Network. Current Proteomics, 2018, 15, 159-164.	0.3	0
1091	Urothelial Carcinoma in Situ. Encyclopedia of Pathology, 2019, , 1-4.	0.0	0
1092	Inverted Urothelial Papilloma. Encyclopedia of Pathology, 2019, , 1-4.	0.0	0
1093	Sclerosing Adenosis, Genitourinary Tract. Encyclopedia of Pathology, 2019, , 1-2.	0.0	0
1094	Staging and Reporting of Renal Cell Carcinomas. , 2020, , 423-436.		0
1095	Sclerosing Adenosis of the Prostate. Encyclopedia of Pathology, 2020, , 365-366.	0.0	0
1096	Identification of gene signature associated with type 2 diabetes mellitus by integrating mutation and expression data. , 2020, , .		0
1097	Inverted Urothelial Papilloma. Encyclopedia of Pathology, 2020, , 158-161.	0.0	0
1098	Pathology of the Benign and Malignant Diseases of the Prostate. , 2020, , 1-12.		0

#	ARTICLE	IF	CITATIONS
1099	Urothelial Carcinoma In Situ. Encyclopedia of Pathology, 2020, , 460-463.	0.0	0
1100	Spectrum of incipient (or precursor) lesions in the mucosa of the seminal vesicles. Pathology Research and Practice, 2022, 229, 153737.	2.3	0
1101	Basic Anatomy and Histology of the Prostate. , 0, , 1-9.		0
1102	Inflammatory and Tumor-like Conditions of the Prostate. , 0, , 10-28.		0
1103	Preneoplastic Lesions and Conditions of the Prostate. , 0, , 29-45.		0
1104	Adenocarcinoma of the Prostate. , 0, , 46-59.		0
1105	Gleason Grading of Prostate Cancer. , 0, , 60-76.		0
1106	Histologic Subtypes of Prostatic Carcinoma. , 0, , 77-93.		0
1107	Neuroendocrine Tumors of the Prostate. , 0, , 94-100.		0
1108	Pathologic Prognostic Factors of Prostate Cancer. , 0, , 101-113.		0
1109	Pathology of the Prostate after Treatment. , 0, , 114-126.		0
1110	Basic Molecular Pathology of Prostate Cancer. , 0, , 127-133.		0
1111	Rare Forms of Prostatic Carcinomas. , 0, , 134-140.		0
1112	Tumors and Tumor-like Conditions of the Prostate Stroma. , 0, , 141-148.		0
1113	Soft Tissue and Miscellaneous Primary Tumors of the Prostate. , 0, , 149-156.		0
1114	Metastatic and Secondary Tumors of the Prostate. , 0, , 157-168.		0
1115	Pathology of the Prostatic Urethra. , 0, , 179-192.		0
1116	Testis and Paratesticular Tissues. , 2022, , 607-628.		0

#	ARTICLE	IF	CITATIONS
1117	SELF-EMPLOYMENT IN RUSSIA: PROBLEMS AND PROSPECTS OF LEGAL REGULATION DURING THE COVID-19 PANDEMIC. , 2022, , .		0
1118	Urinary Bladder and Urachus. , 2022, , 551-574.		0
1119	Ductal adenocarcinoma of the prostate with oncocytic morphology. Pathology, 2024, 56, 415-419.	0.7	0
1120	Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management. Urologic Oncology: Seminars and Original Investigations, 2024, 42, 144-154.	1.8	0
1121	Macroscopic evaluation of pathology specimens with large format histology. For the benefit of our service users and patients™. Journal of Clinical Pathology, 0, , jcp-2024-209543.	2.2	0
1122	Applications of Artificial Intelligence in Prostate Cancer Care: A Path to Enhanced Efficiency and Outcomes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2024, 44, .	4.1	0
1123	Urachal and Nonurachal Adenocarcinomas of the Urinary Bladder: A Comprehensive Genomic Profiling Study. JCO Precision Oncology, 2024, , .	3.2	0